

Connecting the World for a Cause




dcvmn
2014



WELCOME NOTE FROM THE PRESIDENT

It is my pleasure to greet our members, partners and friends!

It is worthy reminding ourselves that we are together since 15 years, working for a common cause: to protect people against known and emerging infectious diseases globally, by improving the supply of vaccines from developing countries.

Making a consistent supply of high quality vaccines, which are accessible to all people in developing countries, is not only inscribed on our website and by-laws, but engraved in our hearts. Vaccines are our shared responsibility.

We wish to take up this task and be **responsible**, and beyond we wish to be **reliable** social actors and **responsive** to the needs of the people and the initiatives of governments engaged in improving health globally.

We wish to be responsible in bringing solutions. Indeed vaccine manufacturers have been trusted and **responsible** partners in supporting the achievements of polio-free India, polio-free South-East Asia and we will continue until we achieve a polio-free world.

We wish to be **reliable**, in providing a consistent and timely supply of high quality vaccines. Our vaccines have the full approval of national regulatory agencies, and in addition a growing number of vaccines received the WHO pre-qualification "label", so they are accessible to all populations as needed.

We wish to be **responsive**, using innovative technologies to solve the global health issues. We deliver the right vaccines, where required, when expected.

I wish to thank all members of the industry and collaborating organizations, who have allowed us to hold this Network together for 15 years, and for your continuous and growing commitment to work together for a healthy future.

Sincerely,

A handwritten signature in blue ink, which appears to read 'Mahendra Suhardono'. The signature is fluid and stylized, with a long horizontal stroke extending to the right.

Mahendra Suhardono
DCVMN President

EXECUTIVE COMMITTEE MEMBERS



Mr. Mahendra Suhardono
President
Bio Farma, Indonesia



Dr. G.V.J.A. Harshavardhan
Vice-President
Bharat Biotech International Limited
India



Dr. Akira Homma
Treasurer
Bio-Manguinhos (Fiocruz), Brazil



Dr. Yonglin Wu
China National Biotech Group., China



Dr. Luciana Cezar Cerqueira Leite
Instituto Butantan, Brazil



Dr. Morena Makhoana
The Biovac Institute, South Africa



Dr. Suresh S Jadhav
GAVI Board Alternate
Serum Institute of India, India



Dr. Steven Gao
Xiamen Innovax Biotech Co. Ltd., China








Ms. Mahima Datta
GAVI Board Representative
Biological E. Limited, India



Dr. Sonia R Pagliusi
Executive Secretary
DCVMN International

Member Organizations' Geographical Presence

	Argentina
	Bangladesh
	Brazil
	Cuba
	Egypt
	India
	Indonesia
	Iran
	Mexico
	People's Republic of China
	Republic of Korea
	South Africa
	Taiwan
	Thailand
	Vietnam



Name of the company : **Beijing Minhai Biotechnology Co., Ltd**

Head of Institution : **Dr. Zheng Haifa**

Established : **2004**

Location : **China**

Overview of the company

Beijing Minhai Biotech focuses on the R&D, manufacture and distribution of human use vaccines, the company provides high quality products including Hib conjugate vaccine, DTaP-Hib combined vaccine and MR vaccine. The company located in Bio-medicine Industry Park, DaXing district, Beijing.

Beijing Minhai Biotech has a competitive pipeline of new vaccine products under development including bacterial vaccines, viral vaccines, conjugate vaccines and genetic engineering vaccines. The company has a successful technology transfer with Sanofi Pasteur on rabies vaccine and will continue seek collaboration opportunities domestically and internationally.



Shenzhen Kangtai Biological Products Co., Ltd - the parent company of Minhai - is the largest Hepatitis B vaccine manufacturer in China. The company located in Shenzhen, Guangdong province.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Hib	Hemophilus Influenae type b vaccine	Vial	0.5 ml
DTaP-Hib	Diptheria, Tetanus, accellular Pertussis, and Hemophilus Influenae type b combined vaccine	Vial	0.5 / 5.0 ml
MR	Measles and Rubella combined vaccine	Vial	Lyophilized
Hep B	Hepatitis B vaccine	Vial	10, 20, 60 ug

Future Product Pipe Line

Product Name	Pre Clinical		Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3		
DTaP Vaccine						Q4/2015
23-valent Pneumococcal Polysaccharide Vaccine						Q4/2015
4-valent Meningococcal Polysaccharide Vaccine						Q4/2015
4-valent Meningococcal Conjugate Vaccine						Q4/2015
Inactivated Hepatitis A Vaccine						Q4/2015
HDCV Rabies Vaccine						Q4/2016
Hib Conjugate Vaccine (Lyo)						Q4/2016
13-valent Pneumococcal Conjugate Vaccine						Q4/2016
3-valent Cholera Oral Vaccine						Q4/2017
Influenza Vaccine (Split)						Q4/2017
Recombinant Hepatitis B Vaccine (Hansenula)						Q4/2017
HepA-HepB Combined Vaccine						Q4/2017
Varicella Vaccine						Q4/2017
Zoster Vaccine						Q4/2017
MR & Varicella Vaccine						Q4/2018
DTaP-Hib-sIPV Combined Vaccine						Q4/2018
5-valent Rotavirus Vaccine						Q4/2018
Mumps Vaccine (MuV)						Q4/2019
Genetic HSV						Q4/2019
Genetic EV71 vaccine						Q4/2019
Group B Meningococcal Vaccine						Q4/2019

Areas of Interest for Collaboration

- Technology Transfer
- Vaccine Co-development
- Overseas Registration and Distribution

Contact Details

Name of contact person : **Zhang Qian**

Address : **1 Simiao Road, Bio-medicine Industry Park,
Daxing District**

City : **Beijing**

State :

Location : **China**

Postal code: **102600**

Phone : **+86 10 59613590**

Mobile :

Fax : **+86 10 59613655**

email : **minhaigjhz@126.com**

Website: **www.biominhai.com**



Name of the company : **Beijing Tiantan Biological Products Co., Ltd.**

Head of Institution : **Mr. Zeng Lingbing**, General Manager

Established : **1998**

Location : **China**

Overview of the company

Beijing Tiantan Biological Products Co., Ltd. (abbreviated as TiantanBio) is a state-controlled listed corporation for high technology, engaging in research, manufacturing and marketing of biological products such as vaccines, blood derivatives and diagnostic kits. It's a spin-off company from National Vaccine & Serum Institute (NVI) and became public listed in the China Shanghai Stock Exchange since 1998. TiantanBio owns several subsidiary companies, such as Chengdu Rongsheng Pharmaceutical Co., Ltd., Changchun Keygen Biological Products Co., Ltd., and several serum sampling companies. Now China National Biotec Group Company Limited is its controlling shareholder. At present, TiantanBio has more than 2200 staffs, including a batch of influential senior technical personnel working in the field of R&D, manufacturing and quality assurance.



TiantanBio has the most complete portfolio of vaccines in the National Immunization Program. The leading products are Hepatitis B Vaccine (Yeast Recombinant), Attenuated Measles Mumps and Rubella Combined Vaccine Live, Attenuated Measles and Rubella Combined Vaccine Live, Diphtheria Tetanus and Acellular Pertussis Combined Vaccine Adsorbed, Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell) Live, Japanese Encephalitis Vaccine (Vero Cell) Inactivated, Attenuated Freeze-dried Varicella Vaccine Live, Influenza Vaccine (Spilt Virion) Inactivated, H1N1 Influenza A Vaccine (Spilt Virion) Inactivated, Human Albumin, Human Immunoglobulin (pH4) for Intravenous Injection, Human Immunoglobulin and so on.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
TEMREVAC	Hepatitis B Vaccine made by Recombinant DNA Techniques in Yeast	Ampoule	0.5ml , 1.0ml
	Yellow Fever Vaccine, Live	Vial	6 doses 0.3ml
	Influenza Vaccine (Split Virion), Inactivated	Injector /Vial	0.5ml
RUBEVAC	Rubella vaccine, Live (Human Diploid Cell)	Vial	0.5ml
	Japanese Encephalitis Vaccine (Vero Cell), Inactivated	Vial	0.5ml
	Measles, Mumps and Rubella Combined Vaccine, Live (M/R/MR/MMR)	Vial	0.5ml
	Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell), Live	Pill	1g
Shengdoushi	Freeze-dried Live Attenuated Varicella Vaccine	Vial	0.5ml
Trivac	Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed (DTaP)	Ampoule	0.5ml
	Group A Meningococcal Polysaccharide Vaccine	Vial	10 doses 300µg
	Typhoid Vi Polysaccharide Vaccine	Ampoule	2 doses 1 ml
	Anti-human T Lymphocyte Rabbit Immunoglobulin	Vial	25mg
	Human Hepatitis B Immunoglobulin	Vial	100IU
	Human Albumin	Vial	10ml/25ml/50ml
	Human Immunoglobulin(pH4) for intravenous Injection	Vial	25ml/50ml
	Human Tetanus Immunoglobulin	Vial	250IU

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Recombinant Interferon β 1b					
Meningococcal ACWY Vaccine (Polysaccharide)					
Meningococcal A+C Conjugate Vaccine					
MMR+ Varicella Vaccine					
Pertussis component vaccine					
Inactivated Poliomyelitis Vaccine					

Areas of Interest for Collaboration

- Combined Vaccine
- Large-scale Production Technology
- Quality System
- New Antigen

Contact Details

Name of contact person : **Ms. ZHANG Yucui**

Address : **No. 4 Sanjianfang Nanli, Chaoyang District,
Beijing 100024, P.R.C.**

City : **Beijing**

State :

Location : **China**

Postal code: **100024**

Phone : **+8610-65762911-2543**

Mobile : **+86-13911757012**

Fax : **+8610-65792747**

email : **ttbiozyc@yahoo.com.cn**

Website: **<http://www.tiantanbio.com>**

Name of the company : **Bharat Biotech International Limited**

Head of Institution : **Dr. Krishna M. Ella**, Chairman & Managing Director

Established : **15 February 1996**

Location : **India**

Overview of the company

Bharat Biotech International Limited (BBIL) was incorporated in 1996 at Hyderabad. BBIL was founded by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella, to establish a knowledge base for new vaccine development in the developing world. BBIL has a vision to develop novel vaccines against neglected diseases of the developing world. Dr. V. Krishna Mohan, Executive Director, heads the day to day operations.

BBIL is a multi-dimensional biotechnology company specializing in product-oriented research, development and manufacturing of



vaccines and bio-therapeutics. BBIL is providing affordable, global health care solutions at global quality standards. The company pioneered manufacture of the world's first Cesium chloride- free Hepatitis-B vaccine with HIMAX® technology, a novel purification matrix patented globally. BBIL has successfully manufactured preservative -free Hep-B and Hib vaccines. BBIL is the first Indian company to obtain a global patent for a biotech molecule r-LYSOSTAPHIN, to fight Staphylococcal infections. BBIL was certified by KFDA for the manufacture of parenterals. BBIL has a strong focus on innovation and intellectual property rights, with a belief in "developing our own IPR and not violating IPR". Typhoid Vi polysaccharide Conjugate and Inactivated Japanese Encephalitis vaccines of BBIL have been granted commercial licensure in 2013. Rotavirus Vaccine was granted commercial licensure in 2014. The focus on neglected diseases is unparalleled at BBIL. Vaccines against malaria, chikungunya, human papilloma, MRSA strains and salmonellosis are in the pipeline.

Current Product Pipeline

Product Name	Description	Type Vial/ Ampoule	Presentation 0.5 / 1.0 / 5.0 / 10.0 mL
Revac-B+	Hepatitis B Vaccine, rDNA (Pichia pastoris), 20 µg of HBsAg/1.0 mL (Adult)	Vial	0.5 mL, 1.0 mL, 2.5 mL, 3.0 mL, 5.0 mL, 10.0 mL
Revac-B mcf	Hepatitis B Vaccine, rDNA (Pichia pastoris) Thiomersal Free, 20 µg of HBsAg/1.0 mL (Adult)	Vial	0.5 mL, 1.0 mL
INDIRAB	Rabies Vaccine Vero Cell-Derived; Pitman-Moore strain of Rabies virus Potency ≥ 2.5 I.U./0.5 mL	Vial	0.5 mL, 1.0 mL
TYPBAR	Vi Capsular Polysaccharide Typhoid Vaccine Vi Capsular polysaccharide of S. typhi (Ty2 strain) 25 µg/ 0.5 mL	Vial	0.5 mL, 2.5 mL
HNVAC	H1N1 Pandemic 2009 Flu Vaccine	Vial	0.5 mL,
Typbar TCV	Typhoid Vi Capsular Polysaccharide Conjugate Vaccine	Vial/ PFS	0.5 mL, 2.5 mL
JENVAC	Japanese Encephalitis Vaccine, Inactivated	Vial	0.5 mL, 2.5 mL
ROTAVAC	Rotavirus Vaccine, Live Attenuated, Oral	Vial	0.5 mL, 2.5 mL, 5.0 mL
BIOPOLIO	Trivalent Oral Poliomyelitis Vaccine Live, Attenuated (Sabin) 0.1 mL (2 drops)	Vial	0.5 mL, 1.0 mL
BIOPOLIO M1	Monovalent Oral Poliomyelitis Vaccine Type 1 Live, Attenuated (Sabin) 0.1 mL	Vial	2 mL, 1.0 mL
BIOPOLIO M3	Monovalent Oral Poliomyelitis Vaccine Type 3 Live, Attenuated (Sabin) 0.1 mL	Vial	2 mL, 1.0 mL
BIOPOLIO 1&3	Bivalent Oral Poliomyelitis Vaccine Type 1&3 (Sabin) 0.1 mL	Vial	2.0 mL, 1.0 mL
ComVac4-HB (DPT+Hep-B)	Diphtheria, Pertussis (w), Tetanus, Hepatitis-B Vaccine (Quadrivalent Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
ComVac5 (DPT+Hep B+Hib)	Diphtheria, Pertussis (w), Tetanus, Hepatitis-B & Haemophilus influenzae Vaccine, (Pentavalent Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
ComVac3	Diphtheria Tetanus Pertussis Vaccine (DTP Vaccine) 0.5 mL	Vial	0.5 mL, 2.5 mL, 5.0 mL
REGEN-D 150	r- Human Epidermal Growth Factor Gel 150 µg/gm	Tube	7.5g, 15g, 30g, 60g, 150g
REGEN-D 60	r- Human Epidermal Growth Factor Gel 60 µg/gm	Tube	7.5g, 15g, 30g, 60g, 150g
BIOGIT / FloraNorm	Saccharomyces boulardii (Granular) 250 mg, oral	Sachet	Sachet
BioHib	Purified capsular polysaccharide of Hib [covalently bound to 20-40 µg Tetanus toxoid (PRP-TT)] 10 µg	PFS	0.5 mL

Future Product Pipe Line

- Recombinant Human Growth Hormone
- Recombinant Human Serum Albumin
- Recombinant Parathyroid Hormone
- THR-100 [Recombinant Staphylokinase]
- Lysostaphin for S.aureus infections, topical
- Rotavirus Vaccine Candidate 116E
- Malaria Vaccine Candidate -1 (r-PvRII)
- Malaria Vaccine Candidate -2 (PfMSP-19)
- Malaria Vaccine Candidate -3 (PfF2)

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Recombinant Human Growth Hormone					
Recombinant Human Serum Albumin					
Recombinant Parathyroid Hormone					
THR-100 [Recombinant Staphylokinase]					
Lysostaphin for S.aureus infections, topical					
Rotavirus Vaccine Candidate 116E					Q3 /2014
Malaria Vaccine Candidate -1 (r-PvRII)					
Malaria Vaccine Candidate -2 (PfMSP-19)					
Malaria Vaccine Candidate -3 (PfF2)					

Areas of Interest for Collaboration

- Development of Novel vaccines for Neglected diseases
- Development of novel adjuvants
- Development of novel therapeutics

Contact Details

Name of Contact Person : **Mr. Sai D. Prasad, President**

Address : **Bharat Biotech International Limited
Genome Valley, Shameerpet Mandal**

City : **Hyderabad**

State : **Telangana**

Location : **India**

Postal code: **500 078**

Phone : **+91 40 2348 0567**

Mobile : **+91 9848887866**

Fax : **+91 40 2348 0560**

email : **prasadsd@bharatbiotech.com**

Website: **www.bharatbiotech.com**



Biological E. Limited
Celebrating Life Every Day

Name of the company : **Biological E. Limited**
Head of Institution : **Ms.Mahima Datla**, Managing Director
Established : **1953**
Location : **India**

Overview of the company

Biological E Ltd (BE) is established in the year 1953 in Hyderabad, India. Over the years, we have built up a very significant share in the world of vaccine market, especially in the paediatric range. Our company is a major supplier to the National Immunization Programme (EPI programme) of the Government of India, UNICEF and Pan American Health Organisation. BE envisages becoming a major world player in vaccine business by expanding the product range, market access, manufacturing facilities and infrastructure through investments, increasing manufacturing and development capabilities and marketing agreements.



BE achieved WHO Prequalification status for various vaccines viz. Tetanus, Pentavalent (DTP-HepB-Hib), Japanese Encephalitis, DTP and Td vaccines. BE is the first company to get WHO prequalification by WHO for Japanese Encephalitis vaccine.

As part of continuous efforts to develop new products for human use, BE is currently engaged in development and commercialization of several recombinant, conjugate, bacterial & viral vaccines. BE has productive partnerships with several well respected and renowned Institutions and Public Health Services across the world for joint development of new products to fulfill the unmet needs of India and other regions countries.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
ComBE Five	Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus type B conjugate vaccine (DTPw-Hep B - Hib) – Liquid Pentavalent	Vial (Liquid)	0.5 / 1.0 / 2.5 / 5.0 ml
ComBE Five	Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus type B conjugate vaccine (DTPw-Hep B + Hib) – Lyophilised Pentavalent	Vial (Liquid + Lyophilised)	0.5 / 1.0 / 2.5 / 5.0 ml
BETT	Tetanus Toxoid (adsorbed) (TT)	Vial & Ampoule	0.5 / 5.0 / 10.0 ml
TRIPVAC	Diphtheria, Tetanus and Pertussis vaccine (adsorbed) (DTPw)	Vial	0.5 / 5.0 ml
JEEV	Japanese Encephalitis Vaccine, Inactivated (Strain SA14-14-2 propagated on Vero cell line)	Vial	0.5ml
BE Td	Diphtheria and Tetanus vaccine (Td) (for adolescents & adults)	Vial	0.5 / 5.0 ml
BIVAC	Diphtheria & Tetanus Toxoid (DT)	Vial	0.5 / 5.0 ml
BEVAC	Hepatitis B vaccine (recombinant)	Vial	0.5 / 1.0 / 2.5 / 5.0 ml
TRIPVAC HB	Diphtheria, Tetanus, w-Pertussis, Hepatitis B (recombinant) (DTPw+HepB)	Vial	0.5 / 1.0 / 2.5 / 5.0 ml
HIBE	Haemophilus type b conjugate vaccine lyophilized) (Hib)	Vial (combipack)	0.5 / 1.0 / 2.5 / 5.0 ml

Products in bold are pre-qualified

Future Product Pipe Line

- MR
- Hexavalent
- TCV
- IPV
- Meningococcal

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Vaccines
- Long term partnership

Contact Details

Name of contact person : **Ms. Divya Bijlwan** AVP - SBD
Ms. Kala Naidu, AVP – Intl. Marketing

Address : **Plot No. 623H, Road No.35, Jubilee Hills**

City : **Hyderabad**

State : **Telangana**

Location : **India**

Postal code: **500 033**

Phone : **+91 40 7121 6000**

Mobile :

Fax :

email : **divya.bijlwan@biologicale.co.in**
Intl@biologicale.co.in

Website: **www.biologicale.com**



Name of the company : **Bio Farma**
 Head of Institution : **Iskandar**, President Director
 Established : **August 6, 1890**
 Location : **Indonesia**

Overview of the company

Bio Farma is a state-owned vaccine and antisera manufacturer in Indonesia and it plays a vital role in supporting the National Immunization Program. All of vaccines needed by Government are supplied by Bio Farma. The company has an extensive and strong major goal to responsibly endure its high quality vaccine production whilst holding the awareness to persistently develop the green industry by covering all the aspects of the green industry's activities.

Bio Farma was established in 1890 and throughout its extended history, the company has gone a long way from its beginning and has



proven its strength to the world. This reputation has always been upheld properly and could be reflected from its magnificent qualification and ability to acquire WHO prequalification for its vaccines.

Bio Farma's products are exported to many countries through the direct distribution or UN agencies. Bio Farma actively involve in various international organizations such as WHO, International Vaccine Institute, DCVMN, GAVI and Self Reliance in Vaccine Production-in OIC.

In order to stimulate more breakthroughs ahead, the company pledge to conduct new products research, both independently or collaborate with research institutions. The partnership could lead to new vaccine development or new technology platform.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5 / 1.0 / 5.0 / 10.0 ml
TT	Tetanus Toxoid Vaccine	Vial Uniject	5.0 ml/10.0 ml 0.5 ml
Bio-TT	Tetanus Toxoid Vaccine	Ampoule	0.5 ml
DT	Diphtheria and Tetanus Vaccine	Vial	5.0 ml
Td	Tetanus and Diphtheria Vaccine (for adult)	Vial	5.0 ml
DTP	Diphtheria, Tetanus and whole -cell Pertussis Vaccine	Vial	5.0 ml
DTP-HB	Tetavalent Combination Vaccine	Vial	2.5ml/5.0 ml
HB	Hepatitis B Vaccine	Uniject	0.5 ml, 1.0 ml (for adult)
mOPV, bOPV	Monovalent, bivalent Polio Vaccine	Vial	2.0 ml
tOPV	Trivalent Oral Polio Vaccine	Vial	1.0 ml/2.0 ml
Measles	Measles Vaccine	Vial	10 doses/20 doses
BCG	Tuberculosis Vaccine	Ampoule	20 doses
Flubio	Seasonal flu Vaccine	Vial	0.5 ml/2.5 ml
DTP-HB-Hib (Pentabio)	Diphtheria, Tetanus, Whole-cell Pertussis, Hep-B and Haemophilus Influenzae type b	Vial	0.5 ml/2.5 ml/5.0 ml

Future Product Pipe Line

- Sabin-IPV (sIPV)
- Rotavirus Vaccine
- Flu Vaccine (Pandemic)
- Measles Rubella Vaccine
- Typhoid Conjugate Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Sabin-IPV (sIPV)					2017
Rotavirus Vaccine					2018
Flu Vaccine (Pandemic & Seasonal)					2017
Measles Rubella Vaccine					2015
Typhoid Conjugate Vaccine					2018

Areas of Interest for Collaboration

- Capacity Building
- QMS Training
- Research
- Product Development & Process Innovation
- Marketing & Distribution

Contact Details

Name of contact person : **Iskandar**

Address : **Jl. Pasteur No. 28**

City : **Bandung**

State :**West Java**

Location : **Indonesia**

Postal code: **40161**

Phone :**+62 22 203 3755**

Mobile :

Fax : **+62 22 204 1306**

email : **mail@biofarma.co.id**

Website: **www.biofarma.co.id**

Overview of the company



The Immunobiological Technology Institute - Bio-Manguinhos is a federal laboratory for R&D and production of immunobiologicals in Brazil. Founded in 1976, Bio-Manguinhos is the technical-scientific arm of the Oswaldo Cruz Foundation (Fiocruz) inside the Ministry of health.

This unit plays a strategic role in the supplying of a range of vaccines, biopharmaceuticals and IVD reagents for the Brazilian public health system. Two vaccines are pre-qualified by WHO and are exported through the United Nations Agencies: the yellow fever and polysaccharide meningitis AC vaccines. More than 70 countries have already received these vaccines.

Bio-Manguinhos operates in the research, development and production of immunobiologicals, as well as experience with national and global partnerships for co-development and technological transfer processes.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
DTP + Hib	<i>Diphtheria, Tetanus, Pertussis and Haemophilus influenza type b</i>	5 doses/vial	2.5 ml
Hib	<i>Haemophilus influenza type b</i>	1 and 5 doses/vial	0,5 and 2,5 ml
MMR	<i>Measles, Mumps and Rubella</i>	10 doses/vial	5,0 ml
MMRV	<i>Measles, Mumps, Rubella and Varicella</i>	1 dose/vial	0,5 ml
OPV	<i>Oral Poliomyelitis</i>	25 doses/tube	2,5 ml
IPV	<i>Inactivated Poliomyelitis</i>	10 doses/vial	5,0 ml
Rotavirus	<i>Rotavirus vaccine</i>	1 dose/vial	2,0 ml
10 – valent Pneumococcal	<i>10 – valent Pneumococcal vaccine</i>	1 dose/vial	0,5 ml
Polysaccharide Meningitis AC	<i>Polysaccharide Meningitis AC vaccine</i>	10 doses/vial	1,5 ml
Yellow Fever	<i>Yellow Fever vaccine</i>	5, 10 and 50 doses/vial	0,5, 1,0 and 25 ml
IVD Reagents			
NAT HIV/HCV	<i>Molecular Biology - NAT HIV/HCV</i>	20 tests/kit	–
Imunoblot DPP® HIV -1/2	<i>Rapid Test - Imunoblot DPP® HIV -1/2</i>	20 tests/kit	–
DPP® HIV – 1/2	<i>Rapid Test – DPP® HIV – 1/2</i>	10 and 20 tests/kit	–
DPP® Syphilis	<i>Rapid Test – DPP® Syphilis</i>	20 tests/kit	–
DPP® Canine Leishmaniasis	<i>Rapid Test – DPP® Canine Leishmaniasis</i>	20 tests/kit	–
DPP® Leptospirosis	<i>Rapid Test – DPP® Leptospirosis</i>	20 tests/kit	–
Chagas Disease IFA	<i>Immunofluorescence – Chagas Disease</i>	600 tests/kit	–
Canine Leishmaniasis ELISA	<i>ELISA - Canine Leishmaniasis</i>	384 tests/kit	–
Human Leishmaniasis IFA	<i>Immunofluorescence – Human Leishmaniasis</i>	600 tests/kit	–
Helm Test	<i>Kato Katz – Helm Test</i>	100 tests/kit	–
Biopharmaceuticals			
Interferon alpha 2b	<i>Interferon alpha 2b recombinant</i>	3, 5 and 10 MUI/vial	1,0 ml
Erythropoietin	<i>Erythropoietin recombinant</i>	2.000 and 4.000 UI/ vial	1,0 ml
Alphataliglucerase		200 UI/vial	5,0 ml

Future Product Pipe Line

Vaccines pipeline:

- Conjugate Meningitis C vaccine
- DTP/HB/Hib vaccine
- DTP/HB/Hib/MenC/IPV vaccine
- Dengue tetravalent vaccine (recombinant)
- Dengue tetravalent vaccine (inactivated)
- Yellow fever vaccine (attenuated)
- Yellow fever vaccine (inactivated)
- Yellow fever vaccine (plant-based vaccine)
- Leptospirosis vaccine (recombinant)
- Measles and Rubella vaccine
- Polysaccharide meningitis B vaccine
- Peginterferon Alpha 2b
- Humanized monoclonal antibody Anti-MRSA
- Humanized monoclonal antibody Anti-CD20
- Flex NAT Kit
- NAT improvement
- DPP® Syphilis improvement
- CD3CD4CD8CD45 kit
- Liquid Microarray

Stage of development of vaccines, biopharmaceutical, kits for laboratory diagnosis:

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Bacterial Vaccines	2	-	1	2	-
Viral Vaccines	6	-	-	-	-
Biopharmaceuticals	2	-	-	1	-
IVD reagents	5	-	-	-	-

Areas of Interest for Collaboration

- Prokaryotic expression
- Eukaryotic expression
- Conjugation
- Plant based

Contact Details

Name of contact person : **Mrs. Denise Maria Lobo Crivelli**

Address : **Avenida Brasil, 4365 – Manguinhos**

Phone : **+55 21 3882-9329**

City : **Rio de Janeiro**

Mobile : **+55 21 99395-0839**

State : **Rio de Janeiro**

Fax : **+55 21 3882-7176**

Location : **Brazil**

email : **dlobo@bio.fiocruz.br**

Postal code: **21040-360**

Website: **http://www.bio.fiocruz.br**



Name of the company : **BioNet-Asia Co., Ltd.**
Head of Institution : **Mr. Vitoon Vonghangool**
Managing Director
Dr. Pham Hong Thai
Managing Director
Established : **2001**
Location : **Thailand**

Overview of the company

BioNet-Asia Co., Ltd is an independent vaccine company focused on the discovery, development, production and supply of vaccines.

BioNet has built a unique network of manufacturers, experts and distributors dedicated to vaccines. We provide our partners with technological and business opportunities and ultimately share this common vision that strategic network collaboration is necessary to deliver rapidly conventional and innovative vaccines to the neediest.



BioNet has been supporting Vaccine Manufacturers in their rapid expansion into international markets, finding and capitalizing on new growth opportunities. We have successfully facilitated several strategic public and private partnerships in the field of development, manufacturing and supply of vaccines worldwide.

BioNet is also uniquely positioned as a key commercial partner for technology transfer, and to collaborate on the development of innovative vaccines for the developing countries.

BioNet has built up a unique vaccine development capacity in Thailand, rapidly becoming a Regional Centre of Excellence in R&D, Clinical Development and the Manufacture of vaccines. We use the most recent technologies available in the field of genetic engineering, protein conjugation and cell-culture in order to produce a broad range of vaccines such as recombinant acellular pertussis, dengue, hepatitis B and conjugate vaccines.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hib	<i>Haemophilus influenzae</i> type b vaccine in combined pediatric formulation	Vial	0.5 ml
TRCS Rabies	Rabies vaccine	Vial	0.5 ml

Future Product Pipe Line

- Acellular pertussis (aP) vaccine
- Meningococcal conjugate vaccine
- Hepatitis B vaccine
- Adult combinations (TdaP based vaccines)
- Pediatric combinations
- Dengue vaccine
- Japanese Encephalitis vaccine
- Chikungunya vaccine
- Human papillomavirus vaccine

Product Name	Product development R&D Phase	Pre Clinical	Clinical			Expected launch date Quarter / Year
			Phase 1	Phase 2	Phase 3	
Acellular Pertussis vaccine						
Adult combination vaccine						
<i>Haemophilus Influenzae</i> type b vaccine						Already transferred the technology and launch the product in Asian country

Areas of Interest for Collaboration

- Marketing and Distribution of vaccines
- Vaccine joint development and R&D collaborations
- Technology transfer for aP, Hib, Rabies
- In- and out-licensing opportunities

Contact Details

Name of contact person : **Dr. Pham Hong Thai**

Address : **Hi-Tech Industrial Estate 81 Moo 1,
Baan Lane, Bang Pa-In**

City : **Ayutthaya**

State : **Ayutthaya**

Location : **Thailand**

Postal code: **13260**

Phone : **+66 3595 0750-8**

Mobile :

Fax : **+66 3595 0759**

e-mail : **info@bionet-asia.com**

Website: **www.bionet-asia.com**



Name of the company : **Cadila Pharmaceuticals Limited**
 Head of Institution : **Shri Dr. Rajiv I.Modi, Chairman & Managing Director**
 Established : **28-02-1991**
 Location : **India**

Overview of the company

Cadila Pharmaceuticals is one of the largest privately held pharmaceutical companies in India. Over the last few decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 90 countries around the world. It is a research-driven integrated healthcare solutions provider with a pharmaceutical product basket of 450 plus in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists.

The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products.



Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drugs applications (INDs) cleared by USFDA.

The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia.

Cadila Pharmaceuticals has recently emerged on the World map with the development of world's first introductions like 'Polycap'- a novel drug combination for prevention of Cardiovascular Heart Disease; and 'Risorine', a boosted Rifampicin dosage for TB treatment. Cadila Pharmaceuticals also has a strong footprint in micropropagation and bioformulation through its Agro division.

Cadila Pharmaceuticals Ltd. has also formed a joint venture with Novavax, Inc. USA. The JV-CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India.

Current Product Pipeline

Product Name	Description	Type Vial/PFS	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Pandemic Influenza	H1N1 vaccine produced from VLP technology	Vial/PFS	0.5 ml/2ml vial
Seasonal Influenza Vaccine	Trivalent Influenza vaccine produced from VLP technology	Vial/PFS	0.5 ml/2ml vial
Rabies vaccine	Recombinant G-Protein produced by VLP technology	Vial/PFS	0.5 ml/2ml vial

Future Products Pipe Line

- HPV Vaccine
- Malaria Vaccine
- Hepatitis B
- Hepatitis E
- Pneumococcal conjugate vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase I	Phase II	Phase III	
Pandemic Influenza					2014
Seasonal Influenza					2014
Rabies Vaccine					2014

Areas of Interest for Collaboration

- Vaccine-recombinant
- Vaccine- cell culture based
- Conjugate vaccine
- Adjuvant (Biological and small molecules)
- Recombinant proteins and Monoclonal antibody for therapeutic use
- In licensing /out licensing

Contact Details

Name of contact person : **Dr. Bakulesh M Khamar**, Executive Director-Research

Address : **Cadila Pharmaceuticals Limited**
"Cadila Corporate Campus"
Sarkhej-Dholka Road, Bhat

Phone : **+91-2718- 225001**

City : **Ahmedabad**

Mobile : **+91-9825325010**

State : **Gujarat**

Fax : **+91-2718-225039**

Location : **India**

e-mail : **bmk@cadilapharma.co.in**

Postal code: **382210**

Website: **<http://www.cadilapharma.com>**



Name of the company : **Center for Research and production of Vaccine and Biological (POLYVAC)**

Head of Institution : **Dr. Nguyen Dang Hien, Director**

Established : **24 January 1994**

Location : **Hanoi, Vietnam**

Overview of the company

Center for Research and Production of Vaccines and Biologicals (POLYVAC) was established in 1994 by the Ministry of Health of Vietnam with the task of carrying out experimental research, application of new technologies for production of Vaccine and biological products

From the end of 1962, the Division of Sabin's Oral Polio Vaccine Production of the NIHE was able to produce 2 million doses of oral polio vaccine for children of North Vietnam. With the great efforts of all professionals and staff, with unity and self sufficiency spirit in



order to fulfill the assigned tasks and duties, the quantity of vaccine produced by the Center has increased every year up to 40 million doses, meeting the national vaccination demand for eventual recognition in 2000 by WHO that Vietnam was polio free.

Besides the production of OPV, Center also conducts research and produces other vaccines such as: IPV, Rotavirus vaccines and Measles vaccines meets GMP/WHO with technology transferred by Japan. At present, Measles vaccine has been licensed. Since 2010, Vietnam will stop importing measles vaccine, while being active in preventing and controlling measles as recommended by WHO. The Rotavirus vaccine is has been licensed also from 2012.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Oral polio vaccine	Tetravalent, live, attenuated oral vaccine	Vial	2ml/20 doses/vial
Measles Vaccine	Freeze-dried, live attenuated vaccine. AIK-C Strain	Vial	5ml/10 doses/vial
Rotavirus vaccine	Live attenuated oral vaccine. Human strain G1P[8]	Vial	2ml/1 dose/vial

Future Product Pipe Line

- Rubella
- Measles-Rubella combine vaccine
- Inactivated Polio vaccine
- bOPV

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
bOPV					Q4 /2015
MR					Q4 /2016
IPV					Q3 /2016

Areas of Interest for Collaboration

Contact Details

Name of contact person : Dr. Nguyen Dang Hien, Director

Address : 135 Lo Duc Street

City : Hanoi

State : Vietnam

Location :

Postal code: 10000

Phone : +84 4 3 8211782

Mobile : +84 913236890

Fax : +84 4 38213203

email : danghien@fpt.vn

Website: polyvac.com.vn



Name of the company : **Changchun BCHT Biotechnology Co.**

Head of Institution : **Dr. Kong Wei**

Established : **March, 2004**

Location : **China**

Overview of the company

Changchun BCHT Biotechnology Co., established in 2004 and located in Changchun, is a biopharmaceutical enterprise engaging in research, development, production and marketing of vaccines, biologics and peptide drugs.

BCHT has well-established innovative platform by the most talented researchers and with the state-of-the-art facility. The management team consists of the members with strong international background and extensive experience in China in biopharmaceutical industry. BCHT owns among the most advanced R&D laboratories and pilot plants for vaccines and

peptide drugs in China. Currently, there are two vaccines, varicella and rabies, in the market and many products, such as HIV vaccine and LAIV vaccine, in its developing pipeline at the different stages. The manufacturing plant, production process and quality assessment and control are fully with the compliance of GMP requirements and some products aim at receiving WHO prequalification in the near future.

BCHT has established a wide cooperation with international partners for technology promotion and product marketing. For example, LAIV is the project collaborated with WHO. The company's products have received the certificate or are in the process of registration for the permit of market access in many countries. BCHT is to strategically explore the international market and business opportunity with the partners.



Current Product Pipeline

Product Name	Description	Type Vial/PFS	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Varicella Vaccine, Live	gelatin-free, validity for 36 months, lyophilized, Oka strain	Vial/PFS	0.5ml/vial
Rabies Vaccine(Vero Cell) for Human Use	Produced with microcarrier bioreactor, with high potency not less than 2.5IU	Vial/PFS	1.0ml/vial

Future Products Pipe Line

- Acellular DTP Vaccine
- Live Attenuated Influenza Vaccine
- HPV Vaccine
- Exenatide
- STa1

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase I	Phase II	Phase III	
Acellular DTP Vaccine	——				2016
Live Attenuated Influenza Vaccine	——				2016
HPV Vaccine	——				2018
Exenatide	——				
Sta1	——				

Areas of Interest for Collaboration

- Vaccines
- Peptide and chemical drugs
- Biologics
- Export

Contact Details

Name of contact person : **Wu Jinchang**

Address : **1260 Huoju Road, Changchun National High-tech Industry Development Area, Changchun Jilin 130012 P.R. China**

City : **Changchun**

State : **Jilin Province**

Location : **China**

Postal code: **130012**

Phone : **+86- 431- 85879036**

Mobile : **15044068371**

Fax : **+86- 431- 8519 5516**

e-mail : **wujinchang@bchtpharm.com**

Website: **http://www.bchtpharm.com**



中国生物技术集团
China National Biotec Group

Name of the company : **China National Biotec Group (CNBG)**

Head of Institution : **Dr. Yang Xiaoming**, President

Established : **1989**

Location : **P.R. China**

Overview of the company

CNBG is a state-owned company and one of the subsidiaries of China National Pharmaceutical Group Company (Sinopharm). It's the largest vaccine and blood products manufacturer and supplier in China and has been dedicated in the field of healthcare for nearly a century. CNBG consists of six institutes of biological products which are located in Beijing, Changchun, Chengdu, Lanzhou, Shanghai, Wuhan respectively. CNBG is also the major shareholder of Beijing Tiantan Biological Products Co., Ltd. and Beijing Vigoo Biological Co., Ltd.



CNBG has nearly 10000 employees, among which more than 4000 are scientists and technicians. CNBG owns dozens of achievements with independent intellectual properties rights and are currently operating more than a hundred SFDA cGMP certified manufacturing lines enabling to manufacture over 200 types of biological products for disease prevention, therapeutic and diagnostic use, also including all the vaccines for Chinese EPI program.

CNBG has successfully integrated a flow of R&D, manufacturing, marketing and post-marketing activities for biological products and has become one of the few companies in the world that could offer the widest range of vaccines with large quantities.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
	Hepatitis B vaccine (yeast)	Ampoule	5,10,20 µg
	BCG vaccine for intradermal injection	Ampoule	0.25mg/5doses
	tOPV(dragee candy)	Pill	1g
Shanliantai	Diphtheria Tetanus and Acellular Pertussis combines(DTaP), Adsorbed	Ampoule/vial	0.5ml
	Measles, Mumps and Rubella combined vaccine, Live(M/R/MR/MM/MMR)	vial	0.5ml
CD.JEV	Japanese Encephalitis Vaccine Live	vial	0.5ml
Mengllingkang	Group A+C Meningococcal Polysaccharide vaccine	Ampoule	100µg/dose,400µg/4doses
	Group A Meningococcal Polysaccharide vaccine	Ampoule	150µg/5doses, 300µg/10doses
Havac	Live attenuated Hepatitis A vaccine	vial	1ml
	Split Influenza virus vaccine	Injector/vial	0.25ml, 0.5ml
Huiyikang	23 Valent Pneumococcal Polysaccharide vaccine	vial	0.5ml
Loutewei	Live Rotavirus Vaccine (oral)	vial	3ml
Keerbe	Haemophilus Influenza type b conjugate vaccine	vial	0.5ml
Shengdoushi	Freeze-dried Live attenuated Varicella vaccine	vial	0.5ml
Wushengxin	Rabies Vaccine for human use(vero cell)	vial	0.5ml X 5vial /dose
	Yellow Fever Vaccine, Live	Ampoule	0.3ml/6doses
	Typhoid Vi Polysaccharide vaccine	Ampoule	1ml/2doses
Sentaobao	Tick- Borne Encephalitis Purified Vaccine	Ampoule	1ml
	Human Albumin	vial	2g,5g,10g,12.5g
	Human Immunoglobulin (pH4) Intravenous Injection	vial	1.25g, 2.5g,5g
	Human Hepatitis B/Tetanus/ Rabies Immunoglobulin	vial	100IU,200IU/ 250IU/ 200IU per vial
Hengli	Botulinum Toxin A for injection	vial	5,10,20 µg
	Murine Monoclonal Antibody Anti-Human CD3 antigen of T Lymphocyte	vial	5ml

Future Product Pipe Line

Product Name	Pre Clinical	IND Filed	Phase 1	Clinical Phase 2	Phase 3	Expected launch date Quarter / Year
Beijing Strain Varicella Live Attenuated Vaccine						
Ev71 Vaccine						
Trivalent Reassortant Rotavirus Vaccine						
Typhoid Vi Conjugate Vaccine						
Group A+C Meningococcal Conjugate Vaccine						
ACYW135 Meningococcal Polysaccharide Conjugate						
Hexavalence Rotavirus Vaccine						
13-valent Pneumococcal Conjugate Vaccine						
Recombinant Hexavalent Human Papillomavirus						
slPV						
Lyophilized Herpes Zoster Inactivated Vaccine						
Measles, Mumps, Rubella and Varicella Combined Vaccine Live (MMRV)						
DTaP+Hib						

Areas of Interest for Collaboration

- Large-scale Production Technology
- Combined Vaccine
- Cell line
- New Antigen
- Adjuvant

Contact Details

Name of contact person : **Ms.TANG Ying ; Ms.QU Liang**

Address : **16th Floor, Fortune Tower B,
No.A4 Huixin-East Street, Chaoyang District**

City : **Beijing**

State : **Beijing**

Location : **P.R. China**

Postal code: **100029**

Phone : **+86 10 8466 3879
+86 10 8466 3787**

Fax : **+86 10 8466 3322**

Mobile : **+86 135 0108 1655
+86 136 2110 6475**

email : **tangying@cnbg.com.cn
quliang@cnbg.com.cn**

Website: **www.cnbg.com.cn**



Name of the company : **EuBiologics, Co. Ltd.**

Head of Institution : **Dr. Yeong-Ok Baek, CEO**

Established : **March 10, 2010**

Location : **Republic of Korea**

Overview of the company

EuBiologics Co., Ltd. is a privately-held Korean biopharmaceutical company providing contract research and manufacturing services to domestic and international clients, in addition to building a portfolio of vaccines designed to improve global public health. The company was established in March 2010 with the objective of becoming a preferred strategic partner providing solutions for the development and manufacturing of biopharmaceutical products. EuBiologics's facilities are designed to manufacture a variety of mammalian cell and microbe-derived, protein-based therapeutics and antibodies. It provides customized services for various stages of product development, including cell line development,

"Good Manufacturing Practice" (GMP) production, validation and regulatory support.

The company has also licensed the manufacturing technology necessary to produce an oral cholera vaccine from the International Vaccine Institute. In parallel with the development of its oral cholera vaccine product ("Euvichol"), EuBiologics is pursuing a number of other vaccines against diseases such as typhoid fever, HPV and norovirus.

The company's administrative headquarters is in Seoul and its manufacturing facilities are located in a biotechnology cluster in Chuncheon, Korea. For additional information about the company, please visit <http://www.eubiologics.com/ENG/>.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml

Future Product Pipe Line

- Oral cholera vaccine
- Typhoid conjugate vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Oral cholera vaccine					2016
Typhoid conjugate vaccine					

Areas of Interest for Collaboration

- Development of bacterial conjugate vaccines
- Development of combo vaccines
- New adjuvant development and application to bacterial vaccines

Contact Details

Name of contact person : Jong Sun Yeam

Address : BioVenture Plaza 3-2, 3-3, 56 Soyanggang-ro

Phone : +82 33 817 4001

City : Chuncheon-si

Mobile : +82 10-5507-0255

State : Gangwon-do

Fax : +82 33 817 4003

Location : Republic of Korea

email : jsun@eubiologics.com

Postal code: 200-160

Website: www.eubiologics.com



Name of the company : **Finlay Institute**
 Head of Institution : **Dr. Concepción Campa Huergo**, President / General Director
 Established : **27th Ave No. 19805, La Coronela La Lisa, Habana City**
 Location : **Cuba**

Overview of the company

The FINLAY INSTITUTE, founded in 1991, is a scientific organization, dedicated to research, development, production and commercialization of human vaccines, internationally recognized in this field. This institution is a world leader in the field of meningococcal vaccine and other classic vaccines included in the Extended Immunization Program (EIP). VA-MENGOC-BC®, created and produced by the Finlay Institute was the first effective vaccine against serogroup B meningococcus.



The almost 1000 members of Finlay's staff constitute the largest capital of Finlay Institute and they have been recognized for their experience in the field of vaccines, more than 60% of them have high technical and professional qualification in the field of vaccine research, development, production and quality control. Many of them have more than 20 years of experience in these specialties, which guarantees the preparation and continuity of the projects with the inclusion of new talents graduated from the universities.

The facilities engaged in the production of vaccines and active pharmaceutical ingredients were designed, built, equipped and they are operated according to cGMP. Some products manufactured in these facilities have been prequalified by WHO.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
VA-MENGOC-BC®	Meningococcal BC vaccine	Vial	0.5/2.5/5.0 ml
vax-MEN-AC®	AC Meningococcal polysaccharide vaccine	Vial	5.0 ml
vax-MEN- ACW ₁₃₅ ®	Meningococcal ACW ₁₃₅ vaccine	Vial	5.0 ml
vax-SPIRAL®	Trivalent leptospirosis vaccine	Vial	0.5/5.0ml
vax-TyVi®	Vi polysaccharide typhoid vaccine	Vial	0.5/5.0/10.0 ml
vax-TET®	Tetanus vaccine	Vial	0.5/5.0/10.0 ml
VA-DIFTET®	Diphtheria-Tetanus vaccine for children	Vial	0.5/5.0/10.0 ml
dT-vax®	Diphtheria-Tetanus vaccine for adults	Vial	0.5/5.0/10.0 ml
DTP-vax®	Diphtheria- Tetanus-wPertussis vaccine	Vial	0.5/5.0/10.0 ml

Future Product Pipe Line

- Cholera vaccine (attenuated)
- Plain ACYW₁₃₅ meningococcal vaccine (porcine components free)
- AW₁₃₅ OMV vaccine
- Plain polysaccharide Vi Vaccine (porcine components free)
- Plain ACYW₁₃₅ X meningococcal vaccine
- AW₁₃₅ X OMV vaccine
- Conjugated Vi polysaccharide vaccines
- Conjugated Meningococcal ACYW₁₃₅ X vaccine
- Onco BCG

Product Name	Pre	Clinical	Expected launch date		
	Phase 1	Phase 2	Phase 3	Quarter	Year
Cholera vaccine (attenuated)					
Plain ACYW ₁₃₅ meningococcal vaccine (porcine components free)					
AW ₁₃₅ OMV vaccine					
Plain polysaccharide Vi Vaccine (porcine components free)					
Plain ACYW ₁₃₅ X meningococcal vaccine					
AW ₁₃₅ X OMV vaccine					
Conjugated Vi polysaccharide vaccines					
Conjugated Meningococcal ACYW ₁₃₅ X vaccine					
Onco BCG					

Areas of Interest for Collaboration

- Cooperated manufacturing
- Vaccine technologycal transfer
- Bacterial vaccines development based on outer membrane vesicles and based on capsule polysaccharides
- Application of novel adjuvants based on serogroup B Neisseria meningitidis outer membrane vesicles and proteoliposome-derived cochleate structure for vaccine development

Contact Details

Name of contact person : **Dr. Concepción Campa Huergo**

Address : **Ave 27 No. 19805, La Coronela, La Lisa,**

Phone : **+ 53 7 208 6086**
+ 53 7 208 0976

City : **Havana**

Mobile : **+ 535 285 0016**

State :

Fax : **+ 53 7 208 6075**

Location : **Cuba**

email : **ccampa@finlay.edu.cu**

Postal code: **11600**

Website: **www.finlay.edu.cu**



Name of the company : **Fundação Ataulpho de Paiva**
 Head of Institution : **Germano Gerhardt Filho**
 Established : **1900**
 Location : **Brazil**

Overview of the company

Fundação Ataulpho de Paiva (FAP) is a nonprofit, philanthropic private institution founded in 1900 and was named Brazilian League Against Tuberculosis. FAP has been promoting scientific advances and producing BCG Moreau Rio de Janeiro vaccine strain since 1930. FAP activities are based on production, research and social assistance programs. The Brazilian Ministry of Health has given competence to the Fundação for manufacturing, importing, exporting, stocking, distribution and repackaging of drugs, raw materials and dietary products.



BCG Moreau Rio de Janeiro is one of the four BCG vaccines considered as Reference Reagent by the World Health Organization (WHO). In 2012 the Moreau strain was studied by 16 laboratories from 13 countries certified by WHO.

The high immunogenicity and low side effects of the Brazilian vaccine have been demonstrated. The genome sequence and proteome analysis of the strain were also studied.

In 2006 IMUNO BCG® was launched in Brazil. It was developed from The BCG Moreau Rio de Janeiro strain. It is used for the treatment of superficial bladder cancer.

Currently, FAP has a new factory under construction to increase the production according to Good Manufacturing Practices (GMP). The institution is also researching for advances in the development of tuberculosis drugs.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
BCG	BCG Vaccine	Vial	1mg/10 doses
IMUNO BCG	IMUNO Therapy	Vial	40mg/Intrabladder

Future Product Pipe Line

Product Name	Pre Clinical		Clinical		Expected launch date Quarter / Year
	Phase 1	Phase 2	Phase 3	Phase 3	

Areas of Interest for Collaboration

Contact Details

Name of contact person : **Luiz Roberto Castello-Branco**

Address : **Av. Pedro II, 260/270 – São Cristóvão**

City : **Rio de Janeiro**

State : **Rio de Janeiro**

Location : **Brazil**

Postal code: **20941-070**

Phone : **+55 21 2589-8670**

Mobile : **+55 99457-6164**

Fax : **+55 21 2589-8934**

email : **branco@bcgfap.com.br**

Website: **<http://www.fundacaoataulphodepaiva.com.br>**



Name of the company : **GreenCross Corporation**

Head of Institution : **Il-Sup Huh**

Established : **1967**

Location : **Republic of Korea**

Overview of the company

Green Cross Corporation (GCC) is one of the leading research based biomedical and pharmaceutical companies in Korea. The corporate headquarter and R&D facilities are located in Yongin. GCC has 3 production plants. Since its establishment in 1967, GCC has pioneered in the field of biopharmaceuticals, such as vaccines, plasma-derivatives, diagnostics, recombinant proteins and therapeutic antibodies.

GCC has been well known for the R&D and commercialization of 'Hepavax B', a world's biggest selling hepatitis B vaccine, 'Hantavax', a world's first epidemic hemorrhagic fever vaccine, and 'Suduvax', a world's second chicken pox vaccine. Starting from the nation's first Albumin production in 1971, it currently manufactures more than 12 plasma fractions including immunoglobulin, anti-hemophilic factors, and anti-thrombin factor. Manufacturing over 250 diagnostic reagents in 41 items, GCC is the leader in the nation's diagnostic reagent sector. Recent innovations include 'rhFVIII (GreenGene™)', a recombinant human coagulant factor VIII and a complete flu pipeline including seasonal flu vaccine (GCFLU®), H1N1 vaccine, avian flu vaccine as well as flu therapeutics, Peramivir. GCC is also pursuing opportunities in rare diseases developing therapies for Hunter syndrome (Hunterase™) which is world 2nd, and is designated as orphan drug by MFDS.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
GC FLU	Generic name: Split virion inactivated Influenza Vaccine A sterile suspension containing influenza virus which is propagated in the allantoic fluid of embryonic chicken egg.	pre-filled syringe	0.5ml, 0.25ml
Japanese Encephalitis Vaccine- GCC inj.	Generic name: Inactivated Japanese Encephalitis Vaccine	Vial	0.5ml, 1ml
Varicella Vaccine – GCC inj.	A sterile suspension containing Japanese Encephalitis virus of Nakayama strain inactivated by formalin		
Varicella Vaccine – GCC inj.	Generic name: Live attenuated Varicella Vaccine A freeze-dried, live attenuated varicella-zoster vaccine. When reconstituted, the product is a transparent suspension of colorless or yellowish color	Vial	0.7ml

* More detailed information of GCC' full list of current product pipeline & future product pipeline is available at www.greencross.com.

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Avian Influenza vaccine					
Adult Td vaccine					
Anthrax vaccine					
Cell Culture Influenza vaccine					
Tdap vaccine					
Varicella Zoster vaccine					

Areas of Interest for Collaboration

- Development and marketing partnership for novel vaccine products
- Co-development and commercialization of biologics for rare disease (Hunter syndrome, Hemophilia A)
- In-Licensing partnership for novel oncology or orphan products
- In-Licensing partnership for novel technology

Contact Details

Name of contact person : **Haiyan Nan**

Address : **303 Bojeong-dong, Giheung-gu, Yongin,**

Phone : **+82-31-260-9106**

City : **Yongin**

Mobile : **+82-10-9401-0410**

State : **Gyeonggi-do**

Fax : **+82-31-260-9408**

Location : **Korea**

email : **hynan@greencross.com**

Postal code: **446-770**

Website: **www.greencross.com**



Name of the company : **Haffkine Bio-Pharmaceutical Corporation Limited**

Head of Institution : _____

Established : **1974**

Location : **India**

Overview of the company

The Haffkine Bio-Pharmaceutical Corporation was incorporated in 1974, aiming to take-up and expand the production of the erstwhile Haffkine Institute and to manufacture standard biological and non-biological products of public health importance. The Company established a subsidiary Company in 1977 viz. Haffkine Ajintha Pharmaceuticals Ltd at Jalgaon, producing tablets, capsules, powders, ointments etc.

Haffkine is engaged in the manufacture and supply of biological and non-biological products especially bacterial and viral vaccines, antisera, toxoids, injectables and pharmaceuticals in the pursuit of its mission of "Service to Mankind in the Health Care Sector".



The Company has contributed significantly towards the universal immunization and the Polio Eradication Programme, launched by the Government of India, ensuring timely supply of Oral Polio Vaccine (OPV) in sufficient quantity.

The Company has WHO-GMP prequalification for its Oral Polio Vaccines (mOPV1, bOPV(1&2) and tOPV) for supply to UNICEF.

Haffkine timely and adequately supplies all its products at affordable prices to all the Public Health Institutions of Government of Maharashtra.

Specific initiatives are underway for meeting the demands for the lifesaving drugs in other States, as well as in other countries. The Company plans to increase vaccine/antibodies production and diversify into the manufacture of newer vaccines of social relevance.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
tOPV	trivalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
bOPV(1&3)	Bivalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
mOPV(1)	Monovalent Oral Polio Vaccine	Vial	2.2 ml (20 doses)
ASVS	Anti Snake Venom Serum	Vial	10 ml
AScVS	Anti Scorpion Venom Serum	Vial	10 ml
ARS	Anti Rabies Serum 300 IU/ml	Vial	5 ml
ADS	Anti Diphtheria Serum 10000IU	Vial	5 ml
ATS	Anti Tetanus Serum 1500IU/ml	Ampoule	1 ml

Future Product Pipe Line

- Tissue Culture Anti Rabies Vaccine (TCARV)
- AGGS

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Measles
- Hep B
- HiB
- IPV
- Pneumococcal vaccine

Contact Details

Name of contact person : Mr. Prakash R. Sabde

Address : Acharya Donde Marg, Parel

City : Mumbai

State : Maharashtra

Location : India

Postal code: 400012

Phone :+91-22-24129320-22
(Direct) +91-22-24150628

Mobile : +91-9422783400

Fax : +91-22-24168578

email : md@vaccinehaffkine.com

Website: www.vaccinehaffkine.com



Name of the company : **Incepta Vaccine Ltd**
 Head of Institution : **Abdul Muktedir**, Managing Director
 Established : **2011**
 Location : **Bangladesh**

Overview of the company

Incepta Vaccine Ltd is the first human vaccine manufacturing company in Bangladesh established with the objective to provide vaccine at an affordable cost.

IVL has state-of-the-art facility compliant with WHO GMP requirements which has the capacity to manufacture 180 million doses per year of any dose size from 0.1 ml to 15 ml.



It has an advanced GMP compliant R&D facility, bulk antigen facility with modern production fermenters, large animal house and well designed spacious several cold rooms (from - 20 0C to +8 0C) to store raw materials and finished products.

IVL has started manufacturing of vaccine from June 2011 and launched 4 vaccines & 2 Immunoglobulins.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Rabies vaccine			
Adsorbed Tetanus vaccine			
Typhoid polysaccharide vaccine			
Hepatitis B vaccine			
Rabies immunoglobulin			
Tetanus Antitoxin			

Future Product Pipe Line

- Meningococcal ACYW polysaccharide vaccine
- Pentavalent vaccine (DPT, HB, Hib)
- Measles vaccine
- Oral Polio vaccine
- Hib vaccine
- Pneumococcal 13 valent conjugate vaccine
- Rotavirus vaccine
- Inactivated Polio vaccine
- Inactivated Influenzae vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

Incepta Vaccine Ltd. is open for collaboration with other vaccine manufacturers and research organizations. We intend to take up projects for co-development of vaccines required for the developing nations. IVL has a large pool of highly talented scientists who can take up projects for quick development of vaccines.

Contact Details

Name of contact person : **Abdul Muktadir**

Address : **40, Shahid Tajuddin Ahmed Sarani
Tejgaon I/A**

City : **Dhaka**

State : **Dhaka**

Location : **Bangladesh**

Postal code : **1208**

Phone : **+880-2-8891688-703**

Mobile : **+88-01711522330**

Fax : **+880-2-8891190**

email : **muk@inceptapharma.com**

Website: **www.inceptapharma.com**



Name of the company : **Indian Immunologicals Limited**

Head of Institution : **Shri K.V.Balasubramaniam**, Managing Director

Established : **1982**

Location : **India**

Overview of the company

National Dairy Development Board set up Indian Immunologicals Limited in 1982. IIL is a major player in the human vaccine market in India, holding the fourth position and focusing on the pediatric and rabies segment with its flagship product "Abhayrab". IIL is also a major supplier of vaccines to India's large Universal Immunization Programme. IIL's concept of "Abhay Clinic", which provides vaccination service by qualified medical practitioners working on franchise basis, is unique.

IIL strongly believes that its mission of "Biotechnology in health care made affordable and accessible" can be actively pursued only with its sound technology base in modern biotechnology.

IIL research efforts are directed at developing frontier technologies in biologicals, diagnostics and vaccines. IIL has research collaborations with several reputed national and international institutes.

IIL exports its products to more than thirty five countries across the world with customer focus in Middle East, Asia Pacific region, Africa and CIS countries.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Abhayrab	Vero cell culture Rabies vaccine	Freeze dried vial with diluent ampoule	0.5 and 1ml
Elovac B	Recombinant Hepatitis B vaccine	Vial	0.5, 2.5 and 5 ml
Abhay TAG	Diphtheria, Pertussis and Tetanus vaccine	Vial	0.5, 1, 5 and 10 ml
Abhay DAG	Diphtheria and Tetanus vaccine	Vial	0.5 and 5 ml
Abhay TOX	Tetanus vaccine	Vial	0.5 and 5 ml
Abhay RIG	Equine Rabies immunoglobulins	Vial	0.5 and 5 ml

Future Product Pipe Line

- Tetravalent vaccine (DPT+H)
- Pentavalent vaccine (DPTH+HiB)
- Japanese Encephalitis vaccine
- Chikungunya vaccine
- Human Papilloma virus vaccine
- Hepatitis A vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- IPV vaccine technology
- Varicella vaccine technology
- Pneumococcal vaccine
- Dengue Vaccine
- Typhoid conjugate vaccine
- Rotavirus vaccine

Contact Details

Name of contact person : **Dr. Anand Kumar, Ph.D,** Deputy Managing Director

Address : **Indian Immunologicals Limited,**
Rakshapuram, Gachibowli Post

City : **Hyderabad**

State : **Andhra Pradesh**

Location : **India**

Postal code: **500 032**

Phone : **+91 40 2300 0542**

Mobile : **+91 96663 39987**

Fax : **91-40-23000213**

email : **anandkumar@indimmune.com**

Website: **www.indimmune.com**



Name of the company : **Institute of Vaccines & Medical Biologicals (IVAC)**

Head of Institution : **Dr. Le Van Be**

Established : **23rd November, 1978**

Location : **Vietnam**

Overview of the company

On November 23rd, 1978, the Ministry of Health made the decision to establish Institute of vaccines and biological substances (changed to INSTITUTE OF VACCINES AND MEDICAL BIOLOGICALS – IVAC from 2006) with functions and responsibilities as following:

To plan and carry out the production of vaccines and serum, mainly to supply the Expanded Program on Immunization in Vietnam (EPI), and the others for prevention and treatment of diseases.

- To do research and apply technological advances in production and development of vaccines, serum and other biological substances.
- To co-operate with organizations in the country and abroad in the research and production of vaccines, serum and other biological substances, in order to expand production and raise their quality.



- To provide training to our staffs, to manage the allocated budget and state-owned property. Step by step to control the products and approach self - sustainability about outlay. IVAC consists of 2 establishments:




- Nha Trang establishment, with an area of 13,946m²
 - o Main establishment of IVAC
 - o Produce vaccines and medical biologicals
 - o Conduct scientific and applied research
- Suối Dầu breeding farm - with an area of 126-hectare, 22 kms from the Southern of Nha Trang
 - o breed testing animals serving research and quality control
 - o Raise horses for producing crude sera
 - o Produce food for cattle, microorganism fertilizer

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
BCG vaccine	Freeze dried vaccine against tuberculosis	Ampoule	10 doses/ampoule
DPT vaccine	Combination vaccines against diphtheria, pertussis and tetanus	Vial	10ml/vial
TT vaccine	Vaccine composed of inactivated tetanus toxins - multidoses	Vial	10ml/vial
TT vaccine	Vaccine composed of inactivated tetanus toxins - monodose	Ampoule	0.5ml/ampoule
SAT	Anti tetanus serum	Ampoule	1500IU/ampoule 1000IU/ampoule
SAR	Equine rabies immune globulin	Vial	1000IU/vial
SAV (SAV-a ; SAV-k)	Purified naja kaouthia antivenin and Purified trimeresurus albolabris antivenin	Vial	1000 LD ₅₀ /vial
Im.BCG	BCG immunotherapy of bladder cancer	Ampoule	37.5mg/ampoule
Superferon	Interferon - 2b	Vial	3000000IU/vial

Future Product Pipe Line

- Pandemic Inactivated Monovalent Influenza Vaccine (H5N1 & H1N1)
- Seasonal Splitted Trivalent Influenza Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
H5N1 Influenza vaccine					
H1N1 Influenza vaccine					

Areas of Interest for Collaboration

- Consolidate, upgrade , apply advanced technique for main products of IVAC: anti-serum, combo vaccines based on frame of DTP...etc
- Build up Suoi Dau breeding farm to be suitable for its potential.
- Upgrade testing animals: species, food, workshop, technical service, etc
- Establish a laboratory room to meet the Good Laboratory Practice (GLP) standards
- Build the personnel organization based on new mechanism, agreeing with national strategy on local vaccine production.
- Join, and associate with both domestic and international institutes in researching on new products.
- Enhance both the quality and quantity of existing vaccines to progress exporting vaccines to foreign markets.
- Consolidate and upgrade the Quality Management system.

Contact Details

Name of contact person : **Dr. Le Kim Hoa**

Address : **9 Pasteur Street**

Phone : **+84 58 3 822 408**
+84 58 3 818 898

City : **Nha Trang**

Mobile : **+84 90 3 504 198**

State : **Khanh Hoa province**


Fax : **+84 58 3 823 815**

Location : **Vietnam**

email : **lekimhoa@dng.vnn.vn**

Postal code : **84**

Website: **www.ivac.com.vn**



Name of the company : **Instituto Butantan**

Head of Institution : **Jorge Kalil**

Established : **1901**

Location : **Brazil**

Overview of the company

Instituto Butantan is a public research center, linked to the São Paulo State Secretary of Health, dedicated to the development of biological products for public health, undertaking basic and applied research, and promoting scientific knowledge. It is currently responsible for providing an expressive amount of all of the nationally produced sera and vaccines freely distributed to the entire population of the country by the Brazilian Ministry of Health.

Butantan develops and produces immunobiological and bio-pharmacological products of interest to public health, generates new information through scientific research, educates and trains human resources in the areas of science and technology, and seeks to promote and stimulate scientific understanding among the public in general.



World renowned in the study of poisonous animals and the venoms and toxins produced by them, Butantan Institute has always attracted new scientific leaders who, together with researchers and postgraduate students, develop research projects in many diverse areas.

Butantan provides the Ministry of Health with ~150 million doses of vaccines/year, such as DTP, Hepatitis B, Influenza and Rabies, and ~400,000 vials/year of hyperimmune sera. It has a surplus production capacity, which can be made internationally available. Butantan constitutes a unique association where basic research, technological development and production allow Brazil – within the National Programs of Public Health – to provide state of art immunological products at the frontiers of knowledge, in a rapidly expanding program of self-sufficiency.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
DTP vaccine	Diphtheria, tetanus and whole cell pertussis vaccine	Vial	5.0 ml
dT vaccine	Adult diphtheria and tetanus vaccine	Vial	5.0 ml
HepB vaccine	Recombinant Hepatitis B vaccine	Vial	5.0 ml
Rabies vaccine	Rabies vaccine produced in Vero cell culture for human use	Vial	5.0 ml
Anti-Diphtheria Hyperimmune sera	Anti-diphtheria toxoid hyperimmune sera	Vial	10.0 ml
Anti-Tetanus Hyperimmune sera	Anti-tetanus toxoid hyperimmune sera	Vial	5.0 ml
Anti-Venoms Hyperimmune sera	Bothropic (5 valent), Bothropic-Crotalic, Botropic-Lachetic, Crotalic (2 valent), Lachetic, Elapidic, Escorpionic, Aracnidic (Loxocelles and Phoneutria), Botulinic AB or E, Rabic	Vial	5.0 ml, 10 ml, 20 ml
Influenza vaccine	Influenza vaccine seasonal and H1N1 produced in eggs	Vial	5.0 ml

Future Product Pipe Line

- Lung surfactant
 - DTPlow vaccine
 - Influenza/adjuvant
 - Dengue vaccine – Collaboration NIH
 - Human IgG
- Rotavirus vaccine – Collaboration NIH
 - Recombinant OncoBCG
 - Herpes papilloma virus vaccine – Tech-Transfer Merck
 - Acellular pertussis - Tech-Transfer Merck
 - Hepatitis A - Tech-Transfer Merck

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Lung surfactant					
DTP low					
Influenza/adjuvant					
Dengue vaccine					

Areas of Interest for Collaboration

- Adjuvants
- Fermentation
- Conjugation

Contact Details

Name of contact person : **Jorge Kalil and Josely Chiarella**

Address : **Av. Vital Brasil 1500**

City : **São Paulo**

State : **SP**

Location : **Brazil**

Postal code: **05503-900**

Phone : **+55 11 2627-9502/3 and +55 11 2627-9512**

Fax : **+55 11 2627-9505**

email : **jorge.kalil@butantan.org.br , josely.chiarella@butantan.gov.br**

Website: **www.butantan.gov.br**



Name of the company : **Laboratorios de Biológicos y Reactivos de México, S.A. de C.V. (Birmex)**

Head of Institution : **Luis Guillermo Francisco Ibarra Ponce de León**

Established : **In Mexico City since 1999. Birmex as an enterprise started in 1999 but, as part of the Ministry of Health, has more than 100 years producing vaccines.**

Location : **Mexico**

Overview of the company

Birmex is a government-owned company that produces, imports and commercializes vaccines, antisera and biological reagents.

Our personnel possess a vast expertise in biologics production which combines with a stringent quality control of the production procedures. This expertise results in the successful updating of facilities, production procedures, and programs aimed to meet Good Manufacturing Practices as certified by the National Regulatory Agency.

Over the years Birmex has evolved into a reliable guarantee of experience and know-how for its customers, incorporating into each product and service:

- The confidence of high quality
- The pledge of an end-to-end service with full tracking and control over shipments at all times, whether by land or air
- The security of on-time distribution to any point in the country – this because Birmex is the only laboratory that delivers to all Mexico's 32 states
- The innovation, competitiveness, honesty and integrity in each process focused on offering solutions that meet the customer's needs
- And finally, the assurance of being with a laboratory whose experience, market knowledge and degree of specialization today make it the leading vaccine manufacturer in Mexico and one of the three principal vaccine-manufacturing countries in Latin America.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
tOPV	Trivalent Sabin Oral Polio Vaccine	Dropper	2.0 ml
Td vaccine	Tetanus and Diphteria Toxins	Vial	5.0 ml
Snake Antiserum	Vial with freeze dried to be reconstituted with 10 mL of Water for Injection as diluent. This serum is made with venoms from the species <i>Crotalus basiliscus</i> and <i>Bothrops asper</i> , and it has also cross reaction against venoms of the species <i>Akistrodon</i> and <i>Sistrurus</i> .	Vial	10.0 ml
Scorpion Antiserum	Vial with freeze dried to be reconstituted with 5 mL of Water for Injection as diluent. This serum is made with venoms from the species <i>Centruroides</i>	Vial	5.0 ml

Future Product Pipe Line

- Bivalent Oral Polio Vaccine (Types 1 and 3).
- DPwT with whole cell pertussis vaccine
- DPaT with acellular pertussis vaccine
- Tdpa with acellular pertussis vaccine
- Sabin IPV (Technology Transference from INTRAVACC).
- Monovalent Oral Polio Vaccine (Types 1, 2 and 3).
- Influenza vaccine in cell culture.

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Bivalent Oral Polio Vaccine (Types 1 and 3).					Q4 / 2015
DPwT					Q3 / 2016
DPaT					Q4 / 2016
Tdpa					Q4 / 2016
Sabin IPV					Q4 / 2018
Monovalent Oral Polio Vaccine (Types 1, 2 and 3).					Q3 / 2018
Influenza vaccine in cell culture.					Q4 / 2018

Areas of Interest for Collaboration

- Combined vaccines (using Sabin IPV antigen).
- Cell-culture based vaccines.
- Scale-up process.
- Plant design (industrial and pilot level).
- Technology transference for vaccine production.
- From bench to patient, vaccine development.

Contact Details

Name of contact person : **Sonia Villaseñor Bustamante, International Business Manager**

Address : **Amores No. 1240, Col. Del Valle**

Phone : **+52 55 54-22-28-73**

City : **Mexico City**

Fax : **+52 55 54-22-28-81**

State : **D.F.**

email : **svillasenor@birmex.gob.mx**

Location : **Mexico**

Website: **www.birmex.gob.mx**

Postal code: **03100**



Name of the company : **LG Life Sciences Ltd.**

Head of Institution : **Il Jae Jung**

Established : **1947**

Location : **Republic of Korea**

Overview of the company

LG Life Sciences(LGLS) has developed and commercialized an array of pharmaceuticals for human and animal applications over the years. Especially for vaccines, LGLS successfully developed hepatitis B vaccine (EUVAX B™ Inj.) which has been exported to more than 80 countries through UN-sponsored programs and represented the major portion of overseas sales. Further to hepatitis B vaccine, LGLS successfully developed tetravalent DTP-based combined vaccines. These include DTaP-HepB(Eutravac™ Inj.) and DTwP-HepB(Euforvac™ Inj.). Both of them were approved by Korean FDA in

year 2008 and showed superior efficacy and safety. LGLS also developed a Hib vaccine(Euhib™ Inj.), as a component of pentavalent vaccine by reconstitution with DTwP-HepB(Euforvac-Hib™ Inj.). In addition, LGLS is developing a fully-liquid pentavalent vaccine(Eupenta™ Inj.), based on the accumulated technology and knowhow, for UN vaccine market. And year 2011, LGLS is selected by WHO as one of tech transfer recipient of sabin IPV. Based on this new technology, LGLS will continue to develop hexavalent and further combined vaccines. Through the long development history on vaccines LGLS accumulated a lot of experiences on vaccines and came to have very strong capability on vaccine development area. In the future, LGLS will remain a leader in life sciences and biotechnology-value added areas that are knowledge intensive.



Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Euvax B™Inj.	Recombinant Hepatitis B vaccine	Vial Liquid	0.5/1.0/5.0ml
Euforvac™Inj.	Adsorbed diphtheria, tetanus, whole cell pertussis & hepatitis B combined vaccine	Vial Liquid	0.5/1.0/5.0ml
Eutravac™Inj.	Adsorbed diphtheria, tetanus, acellular pertussis & hepatitis B combined vaccine	Vial Liquid	0.5ml
Euhib™Inj.	<i>Haemophilus influenzae</i> type b vaccine	Vial Lyophilized	0.5/1.0ml
Euforvac-Hib™Inj.	Adsorbed diphtheria, tetanus, whole cell pertussis, hepatitis B and <i>Haemophilus influenzae</i> type b combined vaccine	Vial Lyophilized	0.5/1.0ml

* More detailed information of LGLS' full list of current product pipeline & future product pipeline is available at www.lgls.com.

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
hGH					
EPO (Espogen®)					
SR-hGH(adult GHD)					
SR-hGH(Pediatric GHD)					
MAB(LBEC0101)					
MAB(LBIM0101)					
MAB(LBAL)					
DTwP-HepB-Hib (Fully liquid)					
sIPV(sabin strain)					
DTP-HepB-Hib-IPV(fully liquid)					
Cell culture influenza vaccine					
HA IDF 1(Skin Rejuvenation)					
HA IDF 2(Skin Rejuvenation)					
LBSA0103(Osteo Arthritis)					
Anti-Adhesion Barrier(Post Operation Adhesio)					

DS: Discovery, **PC:** Preclinical Studies, **MKT:** Market, **GHD:** Growth Hormone Deficiency, **TS:** Turner's Syndrom, **CRI:** Chronic Renal Insufficiency, **SGA** : Small for Gestational Age, **SR** : Sustained Released , **CRF:** Chronic Renal Failure, **IVF:** In vitro Fertilization, **CML:** Chronic Myeloid Leukemia, **HA:** Hyaluronic Acid, **IDF:** Injectable Dermal Filler

Areas of Interest for Collaboration

- Development and marketing partnership for novel vaccine products
- Marketing alliance for biologics, SR-hGH, EPO, rFSH, etc.
- Global marketing partnership or distributionship for HA based products
- Global marketing partnership or distributionship for Fative®

Contact Details

Name of contact person : **Vaccine Biz.**

Address : **LG Gwanghwamun Bldg.**
92, Sinmunno 2-ga, Jongno-gu

City : **Seoul**

State :

Location : **Republic of Korea**

Postal code: **110-062**

Phone : **+82 0 2 6924 3147**

Mobile :

Fax : **+82 0 2 6924 3059**

email : **kimhs@lgls.com**

Website: **www.lgls.com**



Name of the company : **Liaoning Cheng Da Biotechnology Co., Ltd (CDBIO)**

Head of Institution : **Ms. Zhang XiaoHua**, General Manager

Established : **2002**

Location : **China**

Overview of the company

CDBIO is an integrated biotechnology company engaged in R&D, manufacturing, distribution and sales of vaccine products. In 2002, the company introduced world's leading technology platform---"bioreactor and micro-carrier cell culture technology"---, from which the company has developed rabies vaccine and Japanese Encephalitis vaccine.

Until now, our products have been distributed in almost all over the China as well as more than 15 countries in international markets. According to the statistic data, totally more than 100 million doses of rabies vaccine for human use have been used for rabies prophylaxis during the last 7 years and there is no failure case reported after finishing the whole vaccination schedule. The inactivated Japanese Encephalitis vaccine (Vero cell) has also been launched since 2008 and now it has become a better choice for JE prevention. In 2012, the company built a new manufacturing facility following to the Current GMP regulations and it will come into use in 2013.



Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Rabies vaccine for human use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system Chromatographically Purified High Immunogenicity (>4.5IU/dose before lot release) High safety Preservative free, antibiotics free 	Vial	Liquid solution: 0.5ml/dose Lyophilized powder 0.5ml/dose after reconstitution
Rabies vaccine for veterinary use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system High Immunogenicity (2.0IU/dose) High safety Antibiotics free 	Vial	1ml/vial for one dose 5ml/vial for 5 doses
Inactivated Japanese Encephalitis Vaccine for human use	<ul style="list-style-type: none"> Perfusion Culture by Bioreactor and micro-carrier system Chromatographically Purified Preservative free, antibiotics free High safety High Immunogenicity 	Vial	Liquid solution: 0.5ml/dose Lyophilized powder 0.5ml/dose after reconstitution

Future Product Pipe Line

- Hemorrhagic Fever with Renal Syndrome Bivalent Vaccine
- Combined bacterial vaccine

Product Name	Pre Clinical		Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3		
Hemorrhagic Fever with Renal Syndrome Bivalent Vaccine						2014
Combined bacterial vaccine						2017

Areas of Interest for Collaboration

- We are seeking partnerships with large pharmaceutical company who are interested in developing biotech and vaccine products
- In-licensing Opportunity in China

Contact Details

Name of contact person : **Mr. Wu zhe**

Address : **No. 1, Xinfang Street, Hunnan New District**

City : **Shenyang**

State : **Liaoning Province**

Location : **China**

Postal code: **110179**

Phone : **+86-24-83787033**

Mobile: **+86-13109875430**

Fax : **+86-24-83787033**

email : **zhe66@hotmail.com**

Website: **www.cdbio.cn**



Name of the company : **Medigen Vaccinology Corporation**
 Head of Institution : **Dr. Stanley Chang (CEO/Chairman)**
 Established : **October 22, 2012**
 Location : **Taiwan**

Overview of the company

Medigen Vaccinology Corp. (hereinafter as MVC), a subsidiary of Medigen Biotechnology Corp (hereinafter as MBC), founded in Taiwan in Oct, 2012 with a primary focus on the development of innovative cell-based vaccines and the mass production technology of cell-based vaccines. MVC is a private-own company. Besides MBC, other major shareholders are CESCO Bioengineering co., LTD., and Schweitzer Biotech Company Ltd.

MVC aims to develop state-of-the-art and IP-protected cell-culture technologies for rapid and cost effective vaccine



manufacturing using single-use systems. Evidence has been accumulated that this technology can be used in the production of high-quality influenza vaccines with excellent efficiency and reproducibility. Currently, MVC has two cell-based vaccine products at the clinical development.

Furthermore, to ensure adequate supply of high quality vaccines, MVC plans to build a first PIC/S GMP certified cell-based vaccine plant in Taiwan. The ceremony of ground breaking was held in 2014. The construction and the validation of the vaccine plant expect to complete within 2 to 3 years. MVC commits not only to supply the vaccine for Taiwan people, but also provide vaccines globally to contribute to the human health care in the near future.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml

Future Product Pipe Line

- Enterovirus 71(EV71) Vaccine
- Pandemic Influenza Vaccine (H1N1 & H5N1 & H7N9)
- Seasonal Influenza Vaccine
- Japanese Encephalitis Vaccine

Product Name	Pre Clinical		Clinical		Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
EV71 Vaccine					
H5N1 Influenza vaccine					
H7N9 Influenza vaccine					

Areas of Interest for Collaboration

- Joint development for novel cell-based vaccines
- Marketing and distribution of vaccines
- In licensing / out licensing
- Biologics

Contact Details

Name of contact person : Dr. Ting-Wan Lin

Address : 7F., No.16, Ln.120, Sec. 1, Neihu Rd.,

City : Taipei

State :

Location :

Postal code: 11493

Phone : +886 77450830

Mobile :

Fax : +886 26588980

email : info@medigenvac.com

Website: www.medigenvac.com



Name of the company : **National Institute of Infectious Diseases and Vaccinology**

Head of Institution : **Ching-Len Liao, Ph.D**

Established : **May 2011**

Location : **Taiwan**

Overview of the company

The National Institute of Infectious Diseases and Vaccinology (NIIDV) is a mission-oriented R&D department within the National Health Research Institutes (NHRI) in Taiwan, a non-profit organization established by Taiwan government.

NIIDV was formally established in May 2011 by merging the Division of Infectious Diseases and the Vaccine R&D Center. NIIDV conducts researches on important infectious diseases and advocates for government actions and recommendations to solve healthcare problems. International collaborations are part of NIIDV's endeavors to deal with global infectious diseases. NIIDV has state-of-the-art technology, cGMP facility and expertise to develop novel vaccines and immunotherapeutics.



NIIDV has completed the phase I clinical trial of the MDCK cell-based H5N1 flu vaccines in 2010 and transferred to a local biotech company. The influenza vaccine (H5N1, H7N9) is prepared for phase II trials in 2013. The Vero cell-based EV71 vaccine was also developed and the phase I clinical trial has been completed in 2012. The meningococcal B recombinant vaccine is developed and going into phase I clinical trial. To meet national health needs, the BCG vaccine is manufacturing and going to be launched in 2015.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
BCG	Technology and product transfer from Taiwan CDC to be launched in 2015. Live freeze - dried BCG vaccine, 30 doses	Ampoule	3 ml
Antivenin	Technology and product transfer from Taiwan CDC to be launched in 2016.	Vial	30 ml
ProVEU	Cell-based flu vaccine	Vial	3 ml
Ev71vac	Cell-based flu EV71 vaccine	Vial	3 ml
MenBvac	Liporprotein-based meningococcal vaccine	Vial	3 ml

Future Product Pipe Line

- Adenovector-based RSV vaccine
 - HPV therapeutic vaccine
 - Recombinant BCG
 - Dengue vaccine
- Influenza vaccine (H7N9, etc.)
 - Bivalent vaccine against hand-mouth-foot disease

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Adenovector-based RSV vaccine					
HPV therapeutic vaccine					
Recombinant BCG					
Dengue vaccine					
Influenza vaccine (H7N9, etc.)					
Bivalent vaccine against hand-mouth-foot disease					

Areas of Interest for Collaboration

- Technology transfer cell-based viral vaccines and lipoprotein technology
- Service contract for GMP Filling and packaging
- Co-development of new vaccines
- Global marketing partnership/distributorship
- Licensing out of vaccine products and platform technology

Contact Details

Name of contact person : **Ms. Amanda Tsao**

Address : **N0 35, Keyan Road, Zhunan Towan**

City : **Miaoli County**

State :

Location : **Taiwan**

Postal code: **35053**

Phone : **+886-37-246166 ext.37856**

Mobile :

Fax : **+886-37-583009**

email : **pmo@nhri.org.tw**

Website: **www.nhri.org.tw**



Name of the company : **National Administration of Laboratories & Institutes of Health Anlis "Dr. Carlos G. Malbrán"**

Head of Institution : **Dr. Gustavo Ríos**

Established : **1996**

Location : **Argentina**

Overview of the company

The National Administration of Laboratories and Institutes of Health ANLIS "Dr. Carlos G. Malbrán" agency dependent of The Secretary of Policy, Regulation and Institutes of the Ministry of Health of Argentine Nation nucleates eleven institutes and centers located in different places in our country (all of them of recognized performance in their areas of competence).

Its fundamental function understands in science and technical policy associated with various substantive aspects of actions in public health. The Institutional Plan recognizes 6 strategic areas:

1. Research and Technological Development in Health.
2. Health Surveillance and outbreak control.
3. Prevention and Control Disease Programs.
- 4. Production and Supply of Health Strategic Inputs.**
5. Education and Training of Health Human Resources.
6. Information and Communication in Health.

Planned activities in the Production and Supply of Strategic Inputs Area will focus to achieve more equitable access (regarding availability and prices) to technologies and essential medical supplies, with guaranteed quality, safety, effectiveness and cost effectiveness and to promote reasonable and effective use according to their costs.

The global products portfolio of interest includes: viral and bacterial vaccines, immunotherapies (antidotes and antitoxins sera), diagnosis kits and reagents, inputs for reference and proficiency tests sera panels and reference biological standards, biopharmaceuticals and strategic medicines and laboratory animals.

Current Product Pipeline

Product Name		Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Candid # 1		Virus Junin live attenuated vaccine against Argentine Hemorrhagic Fever	10 doses Vial	Lyophilized
Viper venom antiserum, Bothrops bivalent			vial	10.0 ml
Viper venom antiserum, Bothrops tetravalent			vial	10.0 ml
Viper venom antiserum, Crotalus durissus terrificus			vial	10.0 ml
Viper venom antiserum, Micrurus pyrrhocryptus			vial	5.0 ml
Spider venom antiserum, Loxosceles SP			vial	5.0 ml
Spider venom antiserum, Latrodectus SP			vial	2.0 ml
Scorpion venom antiserum, Tityus trivitattus			vial	2.0 ml
Rabies vaccine, FP, human use			vial	2.0 ml
Rabies vaccine, FP, veterinary use			vial (multidose)	50.0 ml
Tuberculin purified protein derivate, human use			vial (multidose)	3.0 ml
BCG for immunotherapy			vial	5.0 ml
Serotyping antisera (Enterobacteriaceae & Vibrio cholerae)			vial	Miscellaneous volumes
Tetanus toxoid – API			N/A	N/A
Diphtheria toxoid – API			N/A	N/A
Pertussis (cellular component) – API			N/A	N/A

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Yellow Fever Vaccine					Implementation of a Quality System training to staff ANLIS in Argentina November 2011
dT vaccine – Diphteria and Tetanus vaccine					Adaptation, renovation and design of the productive areas of the components or API's (used to produce DTP and dT) and acquisition of necessary equipment and instrumentation Execution of the work of the filling and packaging plant and submission a file that includes all equipment and instruments needed in the plant. 2011
DTP vaccine – Diphteria, Tetanus and Pertussis vaccine					
Pentavalent vaccine DTP-HB/Hib					In technology transference management

Kits for diagnosis use: Rotavirus, *Neisseria meningitidis*, *Streptococcus pneumoniae*, Toxoplasmosis, Chagas, Leptospirosis, Brucellosis, etc.

Areas of Interest for Collaboration

- Production technologies
- Quality Control
- Quality Assurance
- Management
- Good Manufacturing Practices
- Clinical trials
- Ethical issues
- Vaccine development
- Vaccine patents politics
- Regulatory issues

Contact Details

Name of contact person : **Flavia M. Consalvo**

Address : **Av. Vélez Sarsfield N° 563**

Phone : **+54 011 4303 1804 ext. 159**

City : **Ciudad Autónoma de Buenos Aires**

Mobile : **+54 011 5594-5332**

State : **Ciudad Autónoma de Buenos Aires**

Fax : **+54 011 4303 1804**

Location : **Argentina**

email : **fconsalvo@anlis.gov.ar**

Postal code: **C1282AFF**

Website: **www.anlis.gov.ar**



Name of the company : **Panacea Biotec Limited (PBL)**

Head of Institution : **Dr. Rajesh Jain, Ph.D.,**

Established : **February 1984**

Location : **India**

Overview of the company

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine manufacturer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey 2006) in India and is also amongst the top 50 pharmaceutical companies in India.

The Vaccines Business has been among the leading suppliers of vaccines to UNICEF and the Government of India's health programs with a focus on critical pediatric vaccines including oral and injectable polio vaccines, and fully liquid combination



vaccines comprising Hepatitis B, DTwP and Hib. The Pharmaceuticals business of the company is focused on super specialty and acute and chronic care segments mainly into organ transplantation, renal diseases, diabetes, oncology, pain management, orthopedics and gastro-intestinal amongst others with key brands in top 5 positions in their respective segments in the India. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities comply with the US-FDA, UK-MHRA, SA-MCC and WHO-CGMP standards. The company is R&D focused with 4 state-of-the-art R&D centers focusing on vaccines, biosimilars, chemistry and biotechnology based drug discovery, novel drug delivery systems and "high barrier to entry generics. The company also has 10 international product patents. The company has over 3800 employees including over 200 highly skilled scientists..

Current Product Pipeline

Product Name	Description	Presentation
EasyFive TT	Fully liquid Hep B, DPT and Hib	SDV, MDV, PFS
Polprotec	Poliomyelitis inactivated vaccine	SDV, PFS
Oral Polio Vaccine	Poliomyelitis vaccine including monovalent Type 1 and 3	Vial
Enivac HB	Inactivated hepatitis B Vaccine	SDV
NovoHib	Hib Vaccine	PFS
Pandyflu	Inactivated H1N1 vaccine	SDV
EasyFour TT	DTP+Hib Vaccine	SDV
PacliAll	First Nano particle paclitaxel product in India	Vial
Pangraf	Tacrolimus	Capsule
Mycept	Mycophenolate Mofetil	Tablet
Glizid	Gliclazide (Plain and Combinations)	Tablet
Sitcom	Euphorbia Prostrata Extract (Plain and Combinations)	Tablet and Cream

Overall, PBL currently has more than 90 brands in its pharmaceutical wing spanning across various therapeutic segments and in different countries (Regulated as well as Non-regulated markets).

Future Product Pipe Line

○ Vaccine

1. Dengue (Tetravalent)
2. Japanese Encephalitis (JE)
3. Conjugated Meningococcal Vaccine
4. Seasonal Flu
5. sIPV based Vaccines

○ Pharmaceuticals

1. In a unique R&D Collaboration with Osmotica Pharmaceuticals (US) & Kremers Urban Pharmaceuticals (US), PBL is developing more than 18 ANDA products for regulated markets (US & Europe).
2. More than 50 % of these products have passed the proof-of-concept phase and are in the commercial batch optimization phase.

Product Name	Expected launch date Quarter / Year
Dengue	2017
Japanese Encephalitis (JE)	2017
Meningococcal	2017
Seasonal Flu	2016

Areas of Interest for Collaboration

- Human Papilloma Virus (HPV) Vaccine
- Rotavirus Vaccine
- Conjugate Typhoid Vaccine

Contact Details

Name of contact person : **Dr. Rajesh Jain, Ph.D.,**

Address : **B-1 Extn./A-27, Mohan Co-op. Industrial Estate,
Mathura Road, New Delhi - 110 044, INDIA**

Phone : **+91-11-4167 9035**

City : **New Delhi**

Mobile :

State : **New Delhi**

Fax : **+91-11-2694 0621**

Location : **India**

email : **rajeshjain@panacea-biotec.com**

Postal code: **110 044**

Website: **www.panacea-biotec.com**



Name of the company : **Production & Research Complex for Pasteur Institute of IRAN**

Head of Institution : **Dr.Hooman Kaghazian, Ph.D.,**

Established : **March 1987**

Location : **Iran**

Overview of the company

Located in the heart of Tehran, Pasteur Institute of Iran (PII) has been providing health care services and related products to the public since 1920. The initial goal of PII establishment was to recognize and combat domestic infectious diseases. PII now is the home of different departments and research centers such as Bacteriology, Biotechnology, Genetics, Parasitology & Mycology, Clinics, and Virology. PII has also been involved in manufacturing a number of parenteral fluids for hospital use since its establishment.

To meet increasing domestic demand PII manufacturing part moved to a new place in outskirt of Tehran in 1988 and assigned as "Production and Research Complex (PRC)". In the new place PII was successfully able to develop its manufactures to varieties of product. Currently PRC productions fall

into three categories:

Vaccines: such as Hepatitis B, BCG, and Anti-Rabies (for veterinary use).

Recombinant Protein Preparations: such as Erythropoietin, Interferon alfa 2b, and Streptokinase. Parenteral fluids.

Therapeutics such as intravesical BCG.

Diagnostic materials used in Medical Laboratories.

Equipped with state-of-the-art machineries PRC now is one of the leading companies in manufacturing biopharmaceuticals in the country and the region.

PRC also benefits from quality assurance (QA) and quality control (QC) departments with close cooperation of the National Regulatory Authorities (NRA).

PRC vision is to employ innovative technologies in order to expand its GMP-oriented products to meet domestic demands as well as looking into foreign markets. In order to commercialize products outside the country, PRC recently applied for pre-qualification status through WHO for its vaccines.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hepatitis B Vaccine (Rec.)	Liquid	Vial	5.0 (10 doses)
BCG Vaccine	Lyophilized	Vial	2.0 (20 doses)
Rabies Vaccine (for animal use)	Liquid	Vial	1.0 (1 dose)
BCG Intravesical (Immune)	Liquid	Vial	120mg/3ml
Erythropoietin (Rec.)	Liquid	Vial	1.0 (2000 I.U.)
Parenteral Solutions	liquid	Vial	50
Diagnostic Kits	Antigens & Antiserums Culture	Vial	
Experimental Animals	Mice- Rabbits- Guinea Pigs- Hamster		

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Interferon Alfa 2b					2014
Streptokinase (Rec.)					2014
Rabies vaccine (for Human use)					2015
MMR Vaccine					
Opaque Agents					
Sodium Bicarbonate					
Pentavalent Vaccine					
Pentaperazole					
Anti Venoms (Snakes & Scorpions)					
Hepatitis B (New Version)					2015
Immunological Diagnostic Kits					
Parenteral Amino Acids Solutions					
PEG Interferon					
VZV Vaccine					
Influenza Vaccine					
Meningitis Vaccine					
Pneumococcal Vaccine					
Hepatitis E Vaccine					
Malaria Vaccine					

Areas of Interest for Collaboration

- Recombinant Biopharmaceuticals
- Cell-Culture-Based Vaccines
- Co Operated Manufacturing
- Vaccine Technology Transfer
- Quality Control, Quality Assurance

Contact Details

Name of contact person : **Vahid Marandi**

Address : **25th Kilometer of Tehran-Karaj Highway**

Phone : **+98 26 36100978**

City : **Karaj**

Mobile :

State : **Alborz**


Fax : **+98 26 3612900**

Location : **IRAN**

email : **vahid_marandi@pasteur.ac.ir**

Postal code: **3159915111**

Website: **http://www.pasteur.ac.ir**



The Queen Saovabha Memorial Institute (QSMI), founded in 1922, has its mission in producing vaccines and snake antivenoms and conducting research on snakes, snake venoms, rabies and related topics.

1. Treatment of animal bites and vaccination against rabies
2. Animal clinic and Rabies diagnosis
3. Travelers immunization clinic
4. Other immunization
5. Snake farm for public
6. Joint collaborative projects in clinical and laboratory diagnosis of human and animals suspect of being rabid, route of rabies vaccine administration (with ministry of public health, livestock department, WHO and US communicable disease center).

II. Research and Development

- 1 Research for improvement of product and diagnosis
- 2 Biomedical and clinical research in areas of rabies, snakes, snake venoms and horses
- 3 Collaboration and joint research projects between QSML and other educational and research institute
- 4 Future plan : New tuberculosis vaccine

III. Production

- Biological products as in headline No.6
- Antidote for the government (Sodium nitrite, Sodium thiosulfate and Methylene blue injection)

57

Future Product Pipe Line

(imported bulk vaccine for formulation and filling) : Estimate launch in year 2015

- **JE vaccines** : lyophilized product of 0.5 ml per vial
- **Influenza** : injection liquid 1 ml per vial of 2 doses
- **Td vaccines** : injection liquid suspension of 2 ml per vial of 2 doses

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
JE vaccines					Q4/2015
Influenza vaccine					Q4/2015
Td vaccines					Q4/2015

Areas of Interest for Collaboration

- New TB vaccine

Contact Details

Name of contact person : **Prof. Dr. Visith Sitprija, Prof. Sumana Khomvilai**

Address :

Phone : **+662 2520131**

City : **Bangkok**

Mobile : **Prof. Dr. Visith Sitprija : 089 8401303**
Prof. Sumana Khomvilai : 081 3759375

State :

Fax : **+662 2540212**

Location : **Thailand**

email : **visithstprj@yahoo.com**
sumanaredcross@gmail.com

Postal code: **10330**

Website: **www.saovabha.co.th**



Name of the company : **Razi Vaccine & Serum Research Institute**

Head of Institution : **Dr. Hamid Kohram**

Established : **1925**

Location : **IR of Iran**

Overview of the company

Razi Vaccine and Serum Research Institute is known as one of the oldest and most reputed scientific centers in the Middle East. This institute began its activities in the year 1925 with producing vaccine against Rinderpest, which at the time had caused large casualties in the cattle population of the country. At present Razi institute is producing more than 60 biological products including human and veterinary vaccines, sera, etc.

Razi institute is governed by a Board of Trustees. The local costumers of the institute products are the Ministry of Health and the Veterinary Organization of the country. The institute is headquartered in the city of Karaj and has six branches in the cities

Mashahad, Ahwaz, Shiraz, Marand, Kerman and Arak. These branches are mainly involved in the production of poultry and other veterinary vaccines.

The Institute is considered a center of research, training and technical assistance for vaccine production and is ready for providing its services and fulfilling the vaccine needs of other developing and neighboring countries.

The objectives are:

- ▶ Research & Production of Medical Vaccines and Antisera
- ▶ Research & Diagnosis of Veterinary and Poultry Diseases
- ▶ Research & Production of Veterinary and Poultry Vaccines
- ▶ Research and Diagnosis of Zoonotic Diseases
- ▶ Biotechnology Research
- ▶ Education & Training



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Trivalent DTP, dT, Td	Diphteria-Tetanus-Pertussis Vaccines	Vial	14 doses/7 ml
Measles	Live Attenuated vaccine (Lyo.)	Vial	10 doses/5 ml
Mumps, Rubella	Live Attenuated vaccines (Lyo.)	Vial	1 dose
Polio (type 1,2, and3)	Live Attenuated vaccine	Flakon	15 doses/1.5 ml
MMR , MR, MM	Live Attenuated vaccines (Lyo.)	Vial	10 doses/5 ml
Polyvalent Snake Antivenom	Antivenom	Ampoule	10 , 5
Polyvalent Scorpion Antivenom	Antivenom	Ampoule	5
Anti-Tetanus Serum	Anti Toxin	Ampoule	2
Anti-Diphtheria Serum	Anti Toxin	Vial	5
Anthrax	Live vaccine	Bottle	100
Blackleg (Cattle)	Inactivated vaccine	Bottle	250
Polyvalent Enterotoxaemia (Sheep & Goat)	Inactivated vaccine	Bottle	250
Brucella Melitansis Strain Rev. 1	Live vaccine (Lyo.)	Vial	100
Brucella Abortus Strain IRIBA	Live vaccine (Lyo.)	Vial	20
Agalactia & Pasterulosis (Cattle & Buffalo)	Inactivated vaccines	Bottle	100
Tetanus (Horse)	vaccine	Vial	20
Rinderpest, Sheep Pox, Goat pox	Live vaccines (Lyo.)	Vial	100
Foot and Mouth Disease (FMD)	Inactivated vaccine	Bottle	250
Bovine Theileriosis	Attenuated vaccine	Vial	12
Fowl Cholera	Inactivated vaccine	Bottle	100
Fowl Pox	Live vaccine (Lyo.)	Vial	1000 , 2000
Infectious Laryngotracheitis	Live vaccine (Lyo.)	Vial	1000 , 2000
Fowl Infectious Bronchitis H-120 & H-52	Live vaccines (Lyo.)	Vial	1000 , 2000
Newcastle La Sota , Newcastle B1	Live vaccines (Lyo.)	Vial	1000 , 2000,4000
Inactivated Influenza (oil-emulsion) H9N2	Inactivated vaccine	Bottle	250
Inactivated Newcastle (oil-emulsion) V4	Inactivated vaccine	Bottle	250
Combined oil-emulsion H9N2 & V4	Inactivated vaccine	Bottle	250
Combined IB (H-120) / ND (B1)	Live vaccine	Vial	2000

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Peste des Petits Ruminants (PPR)					Licensed & Produced
Combined Live IB (H-120) / ND (La Sota)					
Infectious Bursal Disease (IBD)					
Human Influenza Vaccine					
RS12					
Hib vaccine					
Tetavalent DTP-Hib					
Pentavalent DTP-Hib-HepB					
IPV					

Areas of Interest for Collaboration

- Training in the Fields of Production and QC Tests
- Production of New Recombinant Vaccines (Human, Poultry and Veterinary)

Contact Details

Name of contact person : **Dr. Hamid Kohram**

Address : **Razi Vaccine & Serum Research Institute
Karaj, P.O. Box 31975/148, IR, Iran**

Phone : **+98 26 3455 4658**

City : **Karaj**

Mobile :

State : **Tehran**

Fax : **+98 26 3455 4658**

Location : **IR of Iran**

email : **int@rsvri.ac.ir**

Postal code: **3197619751**

Website: **www.rsvri.ac.ir**



Name of the company : **Serum Institute of India Ltd.,**

Head of Institution : **Dr. Cyrus.S. Poonawalla,** Chairman & Managing Director

Established : **1966**

Location : **India**

Overview of the company

Serum Institute of India Ltd. (SII) founded in 1966 by a true visionary Dr. Cyrus Poonawalla, is now India's # 1 Biotech Company and the World's 5th largest vaccine manufacturer (by volume) with an installed annual production capacity of over 1 billion doses of various vaccines. It is also one of the largest suppliers of WHO prequalified vaccines to U.N. Agencies catering to over



140 countries; and also recognized as a reliable largest source of high quality & affordable vaccines and biologicals. It is estimated that 1 out of every 2 children immunized globally get at least one vaccine produced by SII. SII is also now the proud owner of Bilthoven Biologicals, The Netherlands.

SII products are also registered in several countries including Switzerland. This impact has been large enough to make global agencies such as WHO, PATH, NIH, NVI/RIVM, CBER/USFDA & BMGF to work with SII to develop newer vaccines. The production facilities of SII are the best in terms of equipment and human resources; essential to ensure high quality of vaccines. The manufacturing facilities conform to WHO cGMP requirements and till date SII's 21 vaccines are prequalified by WHO/Geneva.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
TT *	Tetanus Vaccine	Ampoule	Single dose (0.5 ml)
DT *	Diphtheria and Tetanus Vaccine (Paediatrics)	Vial	10 doses (5 ml)
Td *	Diphtheria and Tetanus Vaccine for Adults & Adolescents	Vial	20 doses (10 ml)
DTP *	Diphtheria-Tetanus-Pertussis Vaccine	Ampoule	1 & 2 doses (0.5/1 ml)
		Vial	10 & 20 doses (5/10 ml)
Q-Vac *	DTP and Hepatitis B Vaccine (Adsorbed)	Ampoule/Vial	0.5ml & 1 ml / 5 ml
Quadravax *	DTP + Hib Vaccine (Lyo. & Liquid)	Vial	0.5ml, 1 & 5 ml
Pentavalent *	DTP Hepatitis B + Hib Vaccine (Lyo. & Liquid)	Vial	0.5ml, 1, 5 & 10 ml
BCG *	BCG Vaccine	Vial	5ml, 10ml/ 10, 20 doses
Measles *	Measles Vaccine Live (Lyo.)	Vial	1, 2, 5 & 10 doses (0.5ml per dose)
Rubella *	Rubella Vaccine Live (Lyo.)		
MR *	Measles and Rubella Vaccine Live (Lyo.)		
MMR *	Measles, Mumps and Rubella Vaccine Live (Lyo.)		
Rabies *	Rabies Vaccine	Vial/Ampoule	1 ml / 1 dose
IPV	Inactivated Poliomyelitis Vaccine	Prefilled Syringe	0.5ml/dose
Nasovac *	Influenza Vaccine, Live Attenuated (Freeze-dried), Pandemic (H1N1)	Vial/Ampoule	1 & 2 doses (0.5ml per dose)
Hep B *	Recombinant Hepatitis B Vaccine (Pediatric & Adult)	Vial/Ampoule	0.5ml & 1ml
		Vial	5 & 10 ml
Hib *	Haemophilus type b Conjugate Vaccine (Lyo.)	Vial	1 dose
MenAfriVac *	Meningococcal A Conjugate Vaccine (Lyo.)	Vial	10 doses
bOPV *	Bivalent Oral Poliomyelitis Vaccine types 1 & 3	Vial	10 & 20 doses
tOPV *	Trivalent Oral Poliomyelitis Vaccine types 1, 2 & 3	Vial	10 & 20 doses
ATS	Tetanus Antitoxin	Ampoule/Vial	1 ml / 5 ml
ADS	Diphtheria Antitoxin	Vial	10 ml
ASVS	Anti-Snake Venom Serum (Lyo.) Asia & Central Africa	Vial	10 ml
ARS	Anti-Rabies Serum	Vial	5 ml

* Products prequalified by WHO for supplies to U.N. Agencies

Future Product Pipe Line

- DTaP vaccine
- Pneumococcal Polysaccharide Vaccine
- Rabies Monoclonal Antibody (RMab)
- Measles Vaccine (Dry Powder)
- Rabies vaccine (Verorab)
- Aerosol Measles vaccine
- Seasonal influenza Vaccine (Live attenuated)
- Rotavirus Vaccine (Lyophilized)
- Pentavalent Meningococcal Conjugate Vaccine (ACYWX)
- Human Papiloma Virus Vaccine (HPV)
- Recombinant BCG (rBCG) Vaccine

Product Name	Pre Clinical	Phase 1	Clinical Phase 2	Phase 3	Expected launch date Quarter / Year

Areas of Interest for Collaboration

- Newer Vaccines development
- Biosimilars
- Monoclonal antibodies

Contact Details

Name of contact person : **Dr. Suresh S. Jadhav**, Executive Director

Address : **212/2, Hadapsar,
Off. Soli Poonawalla Road, Hadapsar**

City : **Pune**

State : **Maharashtra**

Location : **India**

Postal code: **411 028**

Phone : **+91 20 2660 2378, 2660 2978
+91 20 2660 2379**

Mobile : **+91 98230 22248**

Fax : **+91 20 2699 3945, 2699 3921**

email : **ssj@seruminstitute.com**

Website: **www.seruminstitute.com**





Name of the company : **Sinergium Biotech S.A.**

Head of Institution : **Abel Di Gilio** (President)

Established : **2009**

Location : **Argentina**

Overview of the company

Created in 2009, Sinergium Biotech S.A.'s objective is to provide Argentina with a Center of Excellence in research and production of human vaccines, manufactured with the highest quality standards. With a private investment of close to 80 million dollars, Sinergium Biotech is building a state-of-the art 15,000 square meters production facility and will generate 320 employments enabling the training of highly-specialized workforce. Argentina will rely on national production capacities of human vaccines to supply its own market, even in case of pandemics, and to generate exports to the region. Sinergium

Biotech represents a great opportunity for international vaccine producers to develop their production capacity in Argentina and therefore set foot and expand their participation in the South-American region markets. Thanks to the strategic initiative of Sinergium Biotech, Pfizer and the Argentine Ministry of Health, babies and toddler are being vaccinated today against pneumococcus infections, the principal cause of pneumonia and meningitis in children, as part of the national immunization program. With a projected capacity of 20 million doses of trivalent vaccine per year, Sinergium Biotech will place Argentina in the short list of countries relying on their own technology to produce flu vaccine and thus to face possible pandemics.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
VIRAFLÚ	Anti – influenza Vaccine (inactivated surface antigens)	Prefilled Syringe	0.5 ml
VIRAFLÚ PEDIÁTRICA	Anti – influenza Vaccine (inactivated surface antigens)	Prefilled Syringe	0.25 ml

Future Product Pipe Line

- FLUXVIR, anti-influenza vaccine (adjuvant MF59)
- PREVENAR 13

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Contract Manufacturing

Contact Details

Name of contact person : **Augusto Pich Otero**

Address : **Ruta Panamericana Km 38,7
(colectora oeste, ramal Campana)**

City : **Garín**

State : **Provincia de Buenos Aires**

Location : **Argentina**

Postal code: **B1619IEA**

Phone : **+54 11 3220 7300**

Mobile : **+54 9 11 3236 3615**

Fax : **+54 11 3220 7301**

email : **augusto.pichotero@sinergiumbiotech.com**

Website: **www.sinergiumbiotech.com**



Name of the company : **Sinovac Biotech Ltd.**

Head of Institution : **Weidong Yin**

Established : **2001**

Location : **China**

Overview of the company

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuant to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.



Sinovac has a robust pipeline of new vaccine products under development. The Company is currently developing vaccines for Enterovirus 71 (EV 71), Pneumococcal Conjugate Vaccine, Hib, and Meningitis. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for an independently developed inactivated animal rabies vaccine.

Sinovac is open and flexible to discuss any possible collaborative opportunity of international business and has established a clear path to partnering. We are seeking the partners who share the same value as ours

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
Healive®	Inactivated Hepatitis A Vaccine	Vial	0.5, 1.0 ml
Anflu	Split Influenza Vaccine	Vial	0.25, 0.5 ml
Bilive	Hepatitis A and B Combined Vaccine	Vial	0.5, 1.0 ml
PANFLU.1	H1N1 Influenza Vaccine (Split virion)	Ampoule	0.5, 1.0 ml
H5N1	H5N1 Influenza Vaccine (Split virion)	Ampoule	0.5, 1.0 ml
H5N1	H5N1 Influenza Vaccine (Whole virion)	Ampoule	0.5, 1.0 ml
Mumps	Live attenuated vaccine	Vial	0.5ml

Future Product Pipe Line

- EV71 Vaccine
- Human Rabies Vaccine
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Hib Vaccine
- DTaP Vaccine
- HepB Vaccine
- Rotavirus Vaccine
- CA16 Vaccine
- Varicella Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
EV71 Vaccine					Q2/2014
Human Rabies Vaccine					Q2/2016
Pneumococcal Conjugate Vaccine					Q2/2016
Pneumococcal Polysaccharide Vaccine					2016
Hib Vaccine					Q2/2017
DTaP Vaccine					Q2/2017
HepB Vaccine					Q2/2017
Rotavirus Vaccine					Q3/2017
CA16 Vaccine					Q3/2017
Varicella Vaccine					Q2/2016

Areas of Interest for Collaboration

- Oversea distribution
- R&D cooperation
- International business
- FDA registration for vaccines
- Adjuvant technology
- Micro-carrier technology
- Novel vaccine technology

Contact Details

Name of contact person : **Ms. Helen Yang**

Address : **39 Shangdixi Road, Haidian District**

Phone : **+86 10 82799871**

City : **Beijing**

Mobile :

State : **Beijing**

Fax : **+86 10 62963661**

Location : **China**

email : **info@sinovac.com**

Postal code: **100085**

Website: **www.sinovac.com**



Name of the company : **SK Chemicals (Life Science Biz division)**

Head of Institution : **Chang Geun Kim** (CEO and Vice Chairman)
In Serk Lee (Head of Life Science Business)

Established : **1969**

Location : **Republic of Korea**

Overview of the company

SK Chemicals is a member of SK Group, the third largest company group in Korea. Since founded in 1969, it has become one of top pharmaceutical companies in Korea with its strong marketing operation in cardiovascular, neurology and vaccine/ blood preparation fields.

In 2002, SK Chemicals acquired a blood preparation and vaccine specialized pharmaceutical company Dong-Shin and became the No. 1 vaccine company in Korea.



In addition to three manufacturing plants, including a plant for vaccines and blood products, SK Chemicals started building a GMP compliant new vaccine manufacturing facility with single-use and eco-friendly concept in Andong, Korea in 2011 to produce vaccines developed by SK under the joint partnership with the Korean Government. The new facility with 150 million dose capacity will begin production of various vaccine products including cell-culture based vaccines in late 2013.

In terms of the development of vaccine products, several our vaccine candidates entered into clinical trials in Korea this year.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
SK Td vaccine	Adsorbed tetanus-diphtheria combined toxoid for adult	Prefilled syringe	0.5ml
SK DPT-3 vaccine	Diphtheria, Tetanus and Pertussis vaccine	Prefilled syringe	0.5ml
SK influenza 10 vaccine	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
SK influenza IX vaccine	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
SK influenza	Egg based seasonal flu vaccine	Prefilled syringe	0.25/0.5ml
Hepamun prefilled	Recombinant DNA Hepatitis B vaccine	Prefilled syringe	0.5/1ml
FirstHib	Haemophilus influenzae type b conjugated vaccine	Prefilled syringe	0.5ml

Future Product Pipe Line

- Conjugate vaccines
- Recombinant vaccines
- Cell culture based vaccine

Product Name	Pre Clinical		Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3		
Cell culture based influenza vaccine*						2014/2015
Varicella vaccine						2015
Conjugate vaccine						2016
Others						2016

*SK's cell culture influenza vaccine is prepared in SK's own cell culture platform. It is highly notable that SK's technology is capable of producing high-yields of influenza virus compared to egg based production.

Areas of Interest for Collaboration

- Co-development of new vaccines
- Global marketing partnership/distributorship for cell culture influenza vaccines and varicella vaccines
- Licensing-in / out of vaccine products & platform technology

Contact Details

Name of contact person : **Dr. Hun Kim**

Address : **686 Sampyeong-dong, Bundang-gu**

City : **Seongnam-si**

State : **Gyeonggi-do**

Location : **Republic of Korea**

Postal code: **463-400**

Phone : **+82 2 – 2008 – 2008** (Global Business Development Team)

Mobile:

Fax : **+82 2-2008-2959**

email : **lifescience_global@sk.com**

Website: **www.skchemicals.com/eng/main/main.asp**



Name of the company : **The Biovac Institute**
Head of Institution : **Dr Morena Makhoana**
Established : **2003**
Location : **South Africa**

Overview of the company

The Biovac Institute (Biovac) is a Public Private Partnership between the South African government and a private consortium. It was formed in 2003 to re-establish domestic manufacture of human vaccines, and, ultimately, to enable regional response to vaccine-preventable diseases and regional epidemics.

Biovac is the largest distributor of vaccines in South Africa, and imports, labels, packages and distributes vaccines for the South African public sector. Biovac also imports and distributes vaccines to Southern African Development Community (SADC) countries.



It is Biovac's vision is to be a Centre of Excellence rooted in Africa for the development and manufacture of affordable quality vaccines for Africa and the developing world.

In its short history, Biovac has been able to develop capacity and know-how in conjugate vaccines. The established technology platform includes bacterial fermentation, polysaccharide purification, conjugation and the associated analytical methods. Product-development partnerships are in place with a number of international agencies.

Biovac has invested extensively over the last few years in new vaccine manufacturing and testing facilities. Inward technology transfers are under way with a number of global vaccine-manufacturer partners for local manufacture.

Biovac is the only manufacturer of human vaccines in southern Africa. It is based in Cape Town, South Africa.

Current Product Pipeline

Product Name	Description	Type	Presentation
		Vial/Ampoule	0.5/ 1.0 / 5.0 / 10.0 ml
	Hepatitis B	Vial	0.5, 1.0, 5 ml
	Diluent for BCG vaccine	Vial	1ml
	Seasonal influenza vaccine	Vial or prefilled syringe	0.5ml
	Hexavalent vaccine	Vial	0.5ml

Future Product Pipe Line

- Hib (bulk): Biovac has developed its own *Haemophilus influenza* type b vaccine technology and has successfully concluded out-licensing deals
- Influenza (Pandemic)
- Further contract formulation/filling/finishing – various technology transfer products

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

Biovac welcomes the opportunity to evaluate collaborative partnerships related to the development and manufacture of vaccines and other biological products relevant to Africa and other developing countries.

- Inward technology transfers on products relevant to Africa, particularly bacterial and conjugate vaccines.
- Collaborations on conjugate-vaccine product development
- Contract production of bulk antigen – pilot and full-scale GMP
- Sourcing finished products for the local and regional market

Contact Details

Name of contact person : Patrick Tippoo

Address : 15 Alexandra Road, Pinelands

Phone : +27 21 514 5000

City : Cape Town

Mobile :

State : Western Cape

Fax : + 27 86 518 1127

Location : South Africa

email : patrick@biovacinstitute.co.za

Postal code: 7405

Website: www.biovac.co.za



Name of the company : **The Center for Genetic Engineering and Biotechnology**

Head of Institution : **Dr. Luis Herrera Martínez.** Director General

Established : **1986**

Country : **Cuba**

Overview of the company

The Center for Genetic Engineering and Biotechnology (CIGB) since 1986 has become one of the most important research-production facilities at the "Western Havana Bio-Cluster", equipped and staffed to close the cycle from biological research, which means from biotech product and process development, to production, registering, and commercialization. The CIGB has 20 years of experience in the production of recombinant biopharmaceutical molecules such as interferon, Hepatitis B vaccine, Synthetic Haemophilus influenzae type b vaccine, Tetra- and Penta-valent Combined vaccines, streptokinase, epidermal growth factor formulated in different forms, monoclonal antibodies and other products, which are already producing a positive impact on public health in Cuba and a positive cash flow from sales to more than 50 countries.

The CIGB with about 550 scientists and engineers work in more than 50 research and development projects, which involve new vaccines, therapeutic recombinant proteins and peptides, therapeutic monoclonal antibody and diagnostic systems. CIGB project/product portfolio is covered by more than 70 patent applications and manufacture of those arriving into production stage take place under the most stringent GMP conditions leading into international recognition by different authorities.

CIGB is open to implement a coordinated and targeted alliance-building policy, in order to speed up projects, to complement our capacities with those of our new partners, and to open new channels to the most sophisticated markets.

A component of that policy is to anticipate negotiation time and to start alliance building earlier in the product's life cycle. Thus, immersed in this movement, you will find in this document general data about the institution and summaries of eleven projects, which we considered most attractive for negotiation with your organization. However, while the mail proposed focus is set within these propositions, discussions can be opened around other projects of mutual interest as well.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Heberbiovac HB	HB Vaccine	Vial (liquid)	Pediatric and adult doses, single and multidose
Quimi- Hib	Hib Vaccine	Vial (liquid)	Pediatric, single dose
Trivac HB	Tetavalent Vaccine (DPT-HB)	Vial (liquid)	Pediatric and adult doses, single and multidose
Heberpenta L	Pentavalent Vaccine (DPT-HB-Hib). Fully liquid in one vial	Vial (liquid)	Pentavalent Vaccine (DPT-HB+Hib)
Heberon	Interferon's	Vial (liquid & freeze dried)	Several presentations
Hebekinasa	Streptokinase	Vial (freeze dried)	Several presentations
Heberprot-P	Heberprot-P® is a novel and unique medicine indicated for diabetic foot ulcer treatment (DFU). This innovative product contains epithermal growth factor (EGF) as active pharmaceutical ingredient (APhI) to be applied by intra-lesional infiltration directly in the wound site	Vial (freeze dried)	25 and 75 mcg/vial

Future Product Pipe Line

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Heberprot - P					
HBV vaccine (NASVAC)					
HCV vaccine (CIGB - 230)					
CIGB - 500 (Cytoprotective Agent)					
CEA recombinant antibody fragment (CIGB - M3)					
HPV vaccine					
Prostate cancer vaccine					
CIGB - 370 (Anti- tumor agent)					
CIGB - 166 (anti- VEGF antibody)					
CIGB _ 247 (VEGF vaccine)					
CIGB - 552 (anti -tumor peptide)					
Dengue vaccine					
Dengue anti-viral molecules					
CIGB - 845 (neure-protective agent)					
Peptide for Rheumatoid Arthritis					

Areas of Interest for Collaboration

- Business Strategy for International Partnership in R&D CIGB's Projects
- CIGB is open to implement a coordinated and targeted alliance-building policy, in order to speed up projects, to complement our capacities with those of our new partners, and to open new channels to the most sophisticated markets

Contact Details

Name of contact person : **Dr. Luis Herrera Martinez**

Address : **ave 31. entre 158 y 190. Cubanacan Playa**

Phone : **+53 7 271 6013**
+53 7 271 6022

City : **Havana**

Mobile :

State : **Havana City**

Fax : **+53 7 33 6008**

Country: **Cuba**

email : **luis.herrera@cigb.edu.cu**

Postal code: **PO Box 6162**

Website: **www.cigb.edu.cu**



Name of the company : **The Company for Vaccine and Biological Production No.1 (VABIOTECH)**
Head of Institution : **1 Yersin Street, Hanoi, Vietnam**
Established : **2000**
Location : **Vietnam**

Overview of the company

The Company for Vaccine and Biological Production No.1 is a State-Owned Company which used to belong to The National Institute of Hygiene and Epidemiology (NIHE), Hanoi-Vietnam. From June 2010, VABIOTECH has been transformed into a State Owned One Member Limited Company

VABIOTECH is one of the leading companies in Vietnam in manufacturing, trading, researching and developing a wide range of vaccines and biologicals for human use, analyzing samples of new developed vaccines and biological products, diagnostic kits, therapeutic products, pharmaceuticals; cosmetics, nutrition foods, providing healthcare services... Being the biggest vaccine

manufacturer and supplier for the National Expanded Program on Immunization in Vietnam with GMP-qualified facilities, VABIOTECH is proud of its contribution to prevent, eliminate and gradually eradicate dangerous infectious diseases in order to improve children's health in Vietnam. Currently, VABIOTECH produces 4 vaccines: Hepatitis B, Hepatitis A, Japanese Encephalitis, Oral cholera and a series of diagnosis kits for detection of HBsAg, anti-HBs, anti-HCV and anti-HIV. Besides, VABIOTECH also imports and provides some other vaccines and biological products to meet the market's demand such as: Mumps, Rubella, Meningococcal and Varicella. VABIOTECH is highly committed to provide its best products at favorable price in order to protect Vietnamese people's health and well-being.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hepatitis A Vaccine	Vaccine is a suspension containing inactivated hepatitis A virus (HM 175 hepatitis A strain) absorbed onto aluminum hydroxide.	vial	1.0
Hepatitis B vaccine	It is a non-infectious, inactivated recombinant subunit viral vaccine derived from HBsAg produced in yeast cells using recombinant DNA technology. It is a whitish turbid liquid which is produced by culture of genetically engineered yeast cells which carry the relevant gene of HBsAg, purified and inactivated by several physico-chemical steps such as ultra centrifugation, column chromatography and formaldehyde treatment.	vial	0.5/1.0
Japanese Encephalitis vaccine	The vaccine is produced by VABIOTECH upon technology transfer from BIKEN Institute – Japan, use Japanese encephalitis virus Nakayama strain. This is an inactivated, purified vaccine derived from mouse brain.	vial	1.0/5.0
Cholera vaccine	The vaccine is used against Cholera. The vaccine is produced from Cholera bacteria, consisting of V Cholerae Classical biotype, ELTor and O 139.	vial	7.5

Future Product Pipe Line

- H₃N₂ influenza vaccine (Primary Monkey kidney cell base)
- Hib conjugate vaccine
- Rabies vaccine (vero cell base)
- Japanese Encephalitis vaccine (vero cell base)
- Enterovirus 71 vaccine (EV71)
- S. typhoid Vi conjugate vaccine
- Hepatitis A vaccine (vero cell base)

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
H ₃ N ₂ influenza vaccine					I/2014
Hib conjugate vaccine					I/2016
Rabies vaccine					I/2016
Japanese Encephalitis vaccine					I/2017
Ev71 vaccine					I/2016
S. typhoid Vi conjugate vaccine					I/2016
Hepatitis A vaccine					I/2016

Areas of Interest for Collaboration

- Technology transfer
- Filling and secondary packaging
- Register; collaborate in doing clinical trial, import and market vaccines and biological products in Vietnam's market.
- Export VABIOTECH's products
- Research, develop and commercialize new generation vaccines in Vietnam.

Contact Details

Name of contact person : **Do Tuan Dat, M.D., Ph.D.**

Address : **1, Yersin Street**

Phone : **+ 84 4 39729166**

City : **Hanoi**

Mobile : **+ 84 912007549**

State :

Fax : **+ 84 4 39717711**

Country: **Vietnam**

email : **dotuandat@vabiotech.com.vn**

Postal code: **10000**

Website: **http://www.vabiotech.com.vn**



Name of the company : **The Government Pharmaceutical Organization**
 Head of Institution : **Dr. Suwach Siasiriwattana MD. Managing Director.**
 Established : **5th August 1966**
 Location : **Thailand**

Overview of the company

The Government Pharmaceutical Organization (GPO) of Thailand is a state enterprise under Ministry of Public Health. It was founded in the year 1966 by merging of a pharmaceutical manufacturing plant (founded in 1939) and Pharmaceutical Department (founded in 1901) according to the GPO Act of 1966. The annual revenue of fiscal year 2012 (Oct 2011-Sep 2012) is approx. 400 mUSD. The total pharmaceutical product items are more than 300. The total staff is about 2,700.

The main responsibility of GPO is to produce medicines and pharmaceutical products to serve the national health security system and other medicine supplies. Biological Product Department of GPO is, one of the Production Clusters, responsible for production of vaccines and antisera. At present, staff under this department is about 180. Our current products are JE (MB) vaccine, antiserum of



tetanus and snake venoms. The coming vaccines of dT, TT, DTP DTP-HB and influenza vaccines are under development. The development of influenza vaccine has been supported by WHO and Thai Government including domestic and international networks. The H1N1 2009 PLAIV was registered for pandemic purpose in July 2011. The new strain H5N2 PLAIV is now completed clinical study Phase II and ongoing to submit for registration for pandemic use. The seasonal IIV is being scaled up from pilot scale to industrial scale with technical assistance from KAKETSUKEN, Japan.

The industrial influenza vaccine plant in Saraburi province (120 Km away from Bangkok) is under construction with the support from the government and this will be the new factory for biological products in the future.

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5 / 1.0 / 5.0 / 10.0 ml
Japanese Encephalitis vaccine	Inactivated Japanese Encephalitis vaccine, Beijing strain	Vial	0.5 ml and 5.0 ml
TAT	Tetanus Antitoxin	Ampoule / Vial	1ml / 2ml
Antisnake venom	Anti Cobra, Anti Malayan Pit Viper, Anti Russell's Viper	Ampoule	10ml

Future Product Pipe Line

- Inactivated Influenza vaccine
- Live attenuated Influenza vaccine
- DTP-Hepatitis B vaccine
- dT vaccine
- Tetanus vaccine
- Cell based JE

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	

Areas of Interest for Collaboration

- Development of other vaccines and biopharmaceutical products
- Technology transfer
- Research Collaboration

Contact Details

Name of contact person : **Mr. Sit Thirapakpoomanunt**

Address : **75/1 Rama 6 Road, Ratchthewi, Bangkok 10400**

City : **Bangkok**

State :

Location : **THAILAND**

Postal code:

Phone : **+662 203 8500**

Mobile :**+668 5155 3304**

Fax : **+662 644 8851**

email : **sit.thira@gpo.or.th**

Website: **www.gpo.or.th**



Name of the company : **VACSERA, holding company for biological products & vaccines**

Head of Institution : **Dr. Hamdallah Zedan**

Established : **2003**

Country : **Egypt**

Overview of the company

VACSERA is a state owned company established in 1881 by Health Dept. producing small-pox vaccine followed by Rabies vaccine in 1907, still the only company producing vaccines in Egypt. In 2002 VACSERA was announced as a holding company for biological products & vaccines having 3 affiliated companies in 3 main locations.

1. EGYVAC: The Egyptian Company for Production of Vaccines, Sera and Drugs.
2. EGYBLOOD: The Egyptian Company for Blood Transfusion Services.



3. EGYVET: The Egyptian Company for Drugs & Veterinary Vaccines.

VACSERA mission is to contribute in securing the needs of the country from vaccines (human & veterinary), biotechnological products, blood & blood components, and some laboratory diagnostics, through local manufacturing or procurement to help in the company growth, implementing continuous improvement to all activities, resources and assets of the company.

Egyvac is the sole Producer of vaccines & sera in Egypt & the only supplier of vaccines & sera to the ministries of Health, Defense & interior . The product portfolio includes a wide variety of products that play a major role in the preventive & therapeutic fields. It has two WHO labs & WHO polio regional referenced lab for the EMRO region & WHO National Influenza Center (NIC).

Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Toxovac	Adsorbed Tetanus Toxoid vaccine	Vial / amp	0,5 ml & 5 ml
DT vaccine (for pediatric use)	Diphtheria & Tetanus Toxoids	Vial / amp	0.5 ml & 5 ml
Td Vaccine (for adult use)	Diphtheria & Tetanus Toxoids	Vial / amp	0.5 ml & 5 ml
DPT vaccine	Diphtheria & tetanus toxoids & inactivated <i>Bordetella pertussis</i>	Vial / amp	0.5 ml & 5 ml
Cholera vaccine	Formaldehyde Killed <i>Vibrio cholera</i>	Vial / amp	1ml & 10 ml
Typhoid vaccine	Formaldehyde Killed <i>Salmonella typhi</i>	Vial / amp	1ml & 10 ml
Mixvac (Typhoid / tetanus vaccine)	Tetanus toxoid & killed <i>Salmonella typhi</i>	Vial / amp	1ml & 10 ml
Meningococcal AC Vaccine	Purified polysaccharide From <i>Neisseria meningitidis</i> of types A&C	Vial	10 ml & 25 ml
Anti- scorpion serum (liquid/lyophilized)	Polyvalent anti- scorpion serum	Amp	1 ml
Snake venom antiserum polyvalent (liquid/ lyophilized)	Polyvalent anti- snake serum	Vial	10 ml
Polyvalent anti – viper venom serum (liquid)	Polyvalent anti – viper serum	Vial	5 ml
Seroviper T (liquid & lyophilized)	Polyvalent anti – viper serum for species present in European environment	Vial	5 ml
Polyvalent anti – viper venom serum (lyophilized)	Polyvalent anti – viper serum	Vial	5 ml
Tetanus antitoxin 30000 IU (therapeutic)	Tetanus antitoxin 30000 IU	Vial	10 ml
Tetanus antitoxin 1500 IU (prophylactic)	Tetanus antitoxin 1500 IU	Amp	1 ml
Tetan 3000 IU (prophylactic)	Tetanus antitoxin 3000 IU	Amp	1 ml
Diphtheria antitoxin	Diphtheria antitoxin 10000 IU	Vial	10 ml

Future Product Pipe Line

- Oral Polio Vaccine
- Seasonal Influenza vaccine
- AC meningococcal conjugate vaccine
- AC meningococcal polysaccharide vaccine
- Acellular Pertussis vaccine
- Rabies vaccine
- Combined tetra & penta-vaccines (DTP- Hep B & DTP- Hep B- Hib)
- Haemophilus Influenza vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Oral Polio Vaccine	Pilot Plant scale	Jan 2013			Q2 / 2014
Seasonal Influenza Vaccine	Lab scale				Q4 / 2015
AC meningococcal conjugate vaccine	Lab scale				2016
AC meningococcal polysaccharide vaccine	Preclinical				2016
Acellular Pertussis vaccine	Lab scale				2016
Rabies vaccine	Technology Transfer				

Areas of Interest for Collaboration

Contact Details

Name of contact person : **Dr. Basma Ismael**

Address : **51, Wezaret El-Zeraa st.
Agouza, Giza**

City :

State :

Country: **Egypt**

Postal code: **12311**

Phone : **+202 37611111**

Mobile :

Fax : **+202 37609177**

email : **ceo@vacsera.com**

Website: **www.vacsera.com**



Name of the company : **Walvax Biotechnology Co., Ltd**

Head of Institution : **Li Yunchun**

Established : **2001**

Location : **China**

Overview of the company

Walvax Biotechnology Co., Ltd. (referred to as Walvax) was founded in 2001, which is a modern biological pharmaceutical enterprise engaged in R & D, production and sales of bio-medicine products. Walvax is committed to provide safe bio-medicine (such as vaccines, blood products and so on) with excellent quality and advanced technology for domestic and foreign markets. Walvax's headquarters is located in Kunming, Yunnan Province of China. Currently, Walvax has a modern R & D center in National High-tech Zone of Kunming, and a modern vaccine production base and pilot base in High-tech Zone of Yunnan Yuxi and Jiangsu

Taizhou China Medical City, respectively. Walvax's marketing network covers 30 provinces and cities of China, which includes more than 2000 counties.

In November, 2010, Walvax Biotechnology Co., Ltd. (stock name: Walvax Biotech, and stock code: 300142) listed on Shenzhen Stock Exchange. The operation income of 2013 reached 583.09 million RMB, while the net profit was 103.01 million RMB.

Walvax has successfully developed 20 vaccines, in which Haemophilus Influenzae Type b Conjugate Vaccine, Group A, C Meningococcal Polysaccharide Conjugate Vaccine Freeze Dried, Group A, C, W135 and Y Meningococcal Polysaccharide Vaccine and Group A, C Meningococcal Polysaccharide Vaccine Freeze Dried have been already marketed.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Haemophilus Influenzae Type b Conjugate Vaccine	The product officially launched into market in September 2007. This vaccine is indicated for infants from the age of 2 months to 5 years to induce the active immunization against infectious diseases caused by <i>Haemophilus influenzae</i> type b, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis etc.	Vial	0.5 ml
Haemophilus Influenzae Type b Conjugate Vaccine	In April 2010, Walvax launched a prefilled syringe dosage form of Haemophilus Influenzae Type b Conjugate Vaccine (Hib). Compared to similar products of semi-prefilled syringe dosage form, our prefilled syringe Hib vaccine need just two-step inject operation: Remove the needle shield, and inject. Since no re-dissolution and no need to pierce the vial cap, it can effectively reduce the abundant procedures and waste items in the course of injection. It also can effectively avoid contamination and keep the tip intact. So it can reduce the pain of the vaccinated children.	Pre-filled syringe	0.5 ml
Group A, C Meningococcal Polysaccharide Conjugate Vaccine, Freeze Dried	The product was on market officially in September 2009. The vaccine is indicated for infants from the age of 3 months to 5 years preventing diseases caused by Meningococcal Group A or C, such as cerebrospinal meningitis and septicemia.	Vial	0.5 ml
Group A, C Meningococcal Polysaccharide Vaccine Freeze Dried	The product was on market officially in December 2012. This product is only recommended for Children and adults over the age of 2 years. This vaccine is used to prevent disease caused by the bacteria named "Neisseria meningitidis groups A and group C".	Vial	0.5 ml
Group A, C, W135 and Y Meningococcal Polysaccharide Vaccine	The product was on market officially in December 2012. Currently, this product is only recommended for children above 2 years old and the people who are at the high risk of getting this disease to use. After vaccination, it can prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135.	Vial	1ml /vial/ lyophilized vaccine + 0.5ml / vial /diluent

Future Product Pipe Line

- 23 valent pneumococcal polysaccharide vaccine Tetanus toxoid vaccine, adsorbed
 - Diphtheria, Tetanus and acellular Pertussis Combined vaccine, Adsorbed
 - Tetanus toxoid vaccine, adsorbed
 - Human recombinant papillomatosis poison bivalent vaccine type (16/18) (yeast)
 - Restructuring the HER2 humanized monoclonal antibodies
 - Inactivated split Influenza vaccine
 - Recombined (Hansenula polymorpha) Hepatitis B vaccine
- DTaP+Hib combined vaccine
 - Restructuring of TNF alpha human mouse chimeric monoclonal antibody
 - Recombination anti-tumor necrosis factor alpha all anthropogenic monoclonal antibodies
 - 13 valent pneumococcal conjugate vaccine
 - Group A, C, W135 and Y Meningococcal conjugate Vaccine
 - Immunoglobulin (pH4)
 - Typhoid vaccine

Product Name	Pre	Clinical	Expected launch date		
	Phase 1	Phase 2	Phase 3	Quarter / Year	
23 valent pneumococcal polysaccharide vaccine					
Diphtheria, Tetanus and acellular Pertussis Combined vaccine, Adsorbed					
Tetanus toxoid vaccine, adsorbed					
Human recombinant papillomatosis poison bivalent vaccine type (16/18) (yeast)					

Areas of Interest for Collaboration

Walvax strives to become your best collaboration partner in China. Area of collaboration includes product distributorship, licenses-in/out and manufacture support.
Products for Distribution in Asia (especially Southeast Asia)

- **Vaccine:**
Inactivated Polio Vaccine (IPV), Measles-Mumps-Rubella vaccine (MMR), Varicella vaccine, Rotavirus Vaccine, Pneumococcal Vaccine
- **Source Biologics from world**
 1. Vaccine
 2. Blood Plasma Products
 3. Biologics

Contact Details

Name of contact person : **Gong Su**

Address : **19/F Bldg.9A, Dingyi Tiancheng Residential Quarter, No. 99 Keyuan Road, High & New Tech Development Zone, Kunming, Yunnan Province, China**

City : **Kunming**

State : **Yunnan**

Location : **China**

Postal code: **650106**

Phone : **+86-871-68312659**

Mobile : **+86-15969446240**

Fax : **+86-871-68312567**

email : **yfzxgs@walvax.com.cn**

Website: **http://www.walvax.com**



Name of the company : **Xiamen Innovax Biotech Co., Ltd.**
Head of Institution : **Mr. Steven Gao**, General Manger
Established : **2005**
Location : **China**

Overview of the company

Xiamen Innovax Biotech CO., LTD. (INNOVAX) is a leading company in the field of developing, manufacturing and marketing innovative vaccines with its headquarter and manufacture base in Xiamen, China.

In collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD), INNOVAX has established a core-platform using DNA recombinant technology to express protein in E. coli for vaccine production. Based on this platform, the world's first Hepatitis E Vaccine--Hecolin® has launched in China in October 2012. In addition, a Cervical Cancer Vaccine--Cecolin®, which is under clinical trial phase III and a Genital Warts Vaccine, which has started the phase I clinical trial, have been developed. Besides, a 9-valent HPV vaccine is now at the pre-clinical development stage.



Current Product Pipeline

Product Name	Description	Type Vial/Ampoule	Presentation 0.5/ 1.0 / 5.0 / 10.0 ml
Hecolin®	Hepatitis E Vaccine (E.coli)	Pre-filled Syringe	0.5 ml

Future Product Pipe Line

- Cervical Vaccine (HPV16/18)
- Condyloma Acuminate Vaccine (HPV6/11)
- 9-valent HPV Vaccine

Product Name	Pre Clinical	Clinical			Expected launch date Quarter / Year
		Phase 1	Phase 2	Phase 3	
Cervical Vaccine (Cecolin®,HPV16/18)	2002-2007	2010-2011	2011-2012	2012-2018	2020
Condyloma Acuminate Vaccine (HPV6/11)	2002-2009	2014	2015-2016	2016-2018	2019
9-valent HPV Vaccine	2012-2014	2018	2019-2020	2020-2024	2017

Areas of Interest for Collaboration

- Licensing / Technology transfer
- Overseas distribution
- Product co-development

Contact Details

Name of contact person : **Wendy Huang**

Address : **No.130 Xinyuan Road, Haicang district**

City : **Xiamen**

State : **Fujian Province**

Location : **China**

Postal code: **361022**

Phone : **+86-592-653 6555 -(8118)**

Mobile : **+86-136 6609 6039**

Fax : **+86-592-653 6567**

email : **int@innovax.cn**

Website: **www.innovax.cn**

List of Member Organizations

	Beijing Minhai Biotechnology Co., Ltd	1
	Beijing Tiantan Biological Products Co., Ltd.	3
	Bharat Biotech International Limited	5
	Biological E. Limited	7
	Bio Farma	9
	Bio-Manguinhos - Institute of Technology on Immunobiologicals	11
	BioNet-Asia Co., Ltd.	13
	Cadila Pharmaceuticals Limited	15
	Center for Research and production of Vaccine and Biological (POLYVAC)	17
	Changchun BCHO Biotechnology Co.	19
	China National Biotec Group (CNBG)	21
	EuBiologics, Co. Ltd.	23
	Finlay Institute	25
	Fundação Ataulpho de Paiva	27
	GreenCross Corporation	29
	Haffkine Bio-Pharmaceutical Corporation Limited	31
	Incepta Vaccine Ltd	33
	Indian Immunologicals Limited	35
	Institute of Vaccines and Medical Biologicals	37
	Instituto Butantan	39
	Laboratorios de Biológicos y Reactivos de México, S.A. de C.V. (BIRMEX)	41
	LG Life Sciences Ltd	43
	Liaoning Cheng Da Biotechnology Co., Ltd (CDBIO)	45
	Medigen Vaccinology Corporation	47
	National Administration of Laboratories and Institutes of Health ANLIS "Dr. Carlos G. Malbrán"	49
	National Institute of Infectious Diseases and Vaccinology	51
		
	Panacea Biotec Ltd	53
	Pasteur Institute of Iran	55
	Queen Saovabha Memorial Institute	57
	Razi Vaccine & Serum Research Institute	59
	Serum Institute of India Ltd	61
	Sinergium Biotech S.A.	63
	Sinovac Biotech Ltd.	65
	SK Chemicals (Life Science Biz division)	67
	The Biovac Institute	69
	The Center for Genetic Engineering and Biotechnology	71
	The Company for vaccine and biological production No.1 - VABIOTECH	73
	The Government Pharmaceutical Organization	75
	The Holding Company for Biological Products & Vaccines (VACSERA)	77
	Walvax Biotechnology Co., Ltd	79



braintreehyd@gmail.com

India

DCVMN, 4th Floor, Gumidelli Commercial Complex, 1-10-39 to 44,
Old Airport road, Begumpet, Hyderabad-500016, India
Ph: +91 40 67043947 Fax: +91 40 67043999 Email: admin@dcmvn.org

Switzerland

DCVMN International, Route de Crassier 7, 1262-Nyon - Switzerland
Tel: +41 22 595 13 93 Fax: +41 22 595 67 00
Email: executivesecretary@dcmvn.org

www.dcmvn.org

DEVELOPING | COUNTRIES | VACCINE | MANUFACTURERS | NETWORK